*CURRICULUM VITAE*

# Patricia Elaine Ganey, Ph.D.

---

*CURRENT ADDRESS:*


Patricia Elaine Ganey, Ph.D.
Professor
Department of Pharmacology and Toxicology
Center for Integrative Toxicology
1129 Farm Lane
214 Food Safety and Toxicology Building
Michigan State University
East Lansing, MI 48824
T: 517-432-1761
F: 517-432-2310
ganey@msu.edu


---

*EDUCATION:*

1981-1986 Doctor of Philosophy
Pharmacology and Toxicology-Environmental Toxicology
Michigan State University
East Lansing, MI 48824
Thesis title: *The Role of the Platelet and Platelet Mediators in the Pulmonary Hypertensive Response to Monocrotaline Pyrrole*

1976-1979 Bachelor of Science (graduated *summa cum laude)*
Biological Sciences
The University of Maryland
College Park, MD 20742

1974-1976 Mount Saint Mary's College
Emmitsburg, MD 21727

*POSTDOCTORAL TRAINING:*

1986-1989 Department of Pharmacology and Curriculum in Toxicology
University of North Carolina at Chapel Hill
Chapel Hill, NC 27514
NIH Postdoctoral Fellow; American Liver Foundation Fellow

*PROFESSIONAL EMPLOYMENT:*

2006 - Present Professor
Department of Pharmacology and Toxicology
Michigan State University

1998-2006 Associate Professor
Department of Pharmacology and Toxicology
Michigan State University

1996-1998 Assistant Professor
Department of Pharmacology and Toxicology
Michigan State University

1990-1996 Assistant Professor
Departments of Medicine and of Pharmacology and Toxicology
Michigan State University

*HONORS, FELLOWSHIPS, AND SPECIAL AWARDS:*

2014 Colgate-Palmolive Grant for Alternative Research from the Society of Toxicology
2010 Kenneth E. Moore Distinguished Alumna Award
Department of Pharmacology and Toxicology
Michigan State University
2002 Pfizer Research Excellence Award
1987-1989 National Research Service Award, NIEHS
1987 American Liver Foundation Postdoctoral Fellowship

| | |
|---|---|
| 1986-1987 | NIH Postdoctoral Fellow, Curriculum in Toxicology, The University of North Carolina |
| 1985 | American Society of Pharmacology and Experimental Therapeutics Student Travel Award |
| 1984 | Hazelton Laboratories Corporation Predoctoral Fellowship (sponsored by the Society of Toxicology) |
| 1981-1986 | NIH Predoctoral Trainee, Michigan State University |
| 1979- | Member of Phi Beta Kappa |
| 1979 | Graduated *Summa Cum Laude*, The University of Maryland |
| 1974-1978 | Maryland State Senatorial Scholarship |
| 1974-1976 | Mount Saint Mary's College Academic Scholarship |

---

*SERVICE ACTIVITIES (SINCE 1994)*

**Service Off-campus**

Elected Offices

| | |
|---|---|
| 2017-2018 | President, Society of Toxicology |
| 2016-2017 | Vice President, Society of Toxicology |
| 2015-2016 | Vice President-Elect, Society of Toxicology |
| 2012-2013 | Past-Chair, Division of Toxicology, American Society of Pharmacology and Experimental Therapeutics |
| 2011-2012 | Chair, Division of Toxicology, American Society of Pharmacology and Experimental Therapeutics |
| 2010-2012 | Secretary-Treasurer, Mechanisms Specialty Section, Society of Toxicology |
| 2010-2011 | Chair-Elect, Division of Toxicology, American Society of Pharmacology and Experimental Therapeutics |
| 2008-2010 | Councilor, Society of Toxicology |
| 2006-2008 | Member, Society of Toxicology Awards Committee |
| 2002-2004 | Secretary-Treasurer, Toxicology Division, American Society of Pharmacology and Experimental Therapeutics |
| 2001-2004 | Membership Committee, Society of Toxicology |
| 2003-2004 | Chair, Society of Toxicology Membership Committee |
| 2000-2001 | Past-President, Michigan Regional Chapter of the Society of Toxicology |
| 1999-2000 | President, Michigan Regional Chapter of the Society of Toxicology |
| 1998-1999 | President-Elect, Michigan Regional Chapter of the Society of Toxicology |
| 1999-2001 | Councilor, Mechanisms Specialty Section, Society of Toxicology |

Appointment to Committees

| | |
|---|---|
| 2017-Present | Member, Society of Toxicology Endowment Fund Board |
| 2016-2018 | Member, Society of Toxicology Board of Publications |
| 2015-2018 | Society of Toxicology Representative to Council of the International Union of Toxicologists (IUTOX) |
| 2013-2015 | Member, Society of Toxicology Board of Publications |
| 2007-2008 | Chair, Member Services Strategy Committee, Society of Toxicology |
| 2003-2004 | Member, Nominating Committee, American Society of Pharmacology and Experimental Therapeutics |
| 1998-2001 | Member, Continuing Education Committee, Society of Toxicology |

Appointment to Editorial Boards:

| | |
|---|---|
| 2004-Present | Toxicology |
| 1999-2017 | Journal of Pharmacology and Experimental Therapeutics |
| 1998-Present | Journal of Toxicology and Environmental Health |
| 1999-2005 | Toxicological Sciences |
| 1994-1999 | Fundamental and Applied Toxicology |

Volume Editor

| | |
|---|---|
| 2010 | Volume 9: Hepatic Toxicology in Comprehensive Toxicology, Academic Press, Elsevier, London |

Ad hoc reviewer for the following scientific journals

Biochemical Pharmacology
Biochemistry and Cell Biology
Biochimica et Biophysica Acta
Chemical Research in Toxicology
Chemico-Biological Interactions
Clinical Biochemistry
Clinical Chimistra Acta
Clinical and Experimental Pharmacology and Physiology
Clinical Immunology
Environmental Health Perspectives

Environmental International
Environmental Toxicology and Pharmacology
Hormone and Metabolic Research
Hypertension
Journal of American Physiology
Journal of Leukocyte Biology
Life Sciences
Molecular Pharmacology
Neurotoxicology
Pesticide and Biochemical Physiology
Proceedings of the Society of Experimental Biology
Toxicological Sciences
Toxicology Letters
Toxicology and Applied Pharmacology
Toxicology In Vitro

External reviewer for the following

Subcommittee for the Medical Research Council Centre for Drug Safety Science review 2018-2019
NIEHS Grant Review, periodically
Centennial Center for Environmental Toxicology at the University of Texas Medical Branch, Galveston
NIEHS Environmental Health Center at the University of California, Davis
Seagrant Program, University of Wisconsin-Green Bay
Sarah B. Morris Foundation, University of Missouri, Kansas City
Ireland's Health Research Board
NIH Rapid Access to Interventional Development (RAID) grant program 2006-2007

Consultant for the following

NIEHS Center for Rural Health, Texas A&M University 2000
NTP, Office of the Report on Carcinogens; Aristolochic Acid-related Compounds Expert Panel, 2008
NTP, Office of the Report on Carcinogens; Riddelliine Expert Panel, 2008
Dow Chemical Company
US Food and Drug Administration and Entelos Physiolab, 2006
Consulting Research Evaluation Association (review of results of a toxicity study before federal submission) 2005

Chemical Research in Toxicology: Editor Search 2012
Dainippon Sumitomo Pharma Co., Ltd. 2013
Kiyatec, Inc. 2014
NTP, Office of the Report on Carcinogens, Information Group; Trichloroethylene 2014

Conference organization

Health Consequences from Xenobiotic - Gut Microbiome- Host Interactions, November 2010, Research Triangle Park, NC

Dioxin Toxicity: Mechanisms, Models, & Potential Health Risks, 2008, East Lansing, MI.

Superfund Basic Research Program 20th Anniversary Meeting, 2007, Research Triangle Park, NC.

Bioremediation & Biodegradation: Current advances in reducing toxicity, exposure and environmental consequences, 2002, Asilomar, CA. NIEHS-sponsored conference designed to bring together investigators in a variety of disciplines that are involved in remediation of hazardous chemicals and the evaluation of the effects of remediation processes.

Scientific Basis of Risk Assessment, a meeting of the Michigan Regional Society of Toxicology, 1999, East Lansing, MI. This meeting had three purposes. The first was to bring together nationally recognized scientists to discuss the scientific basis of risk assessment. The second purpose was to showcase graduate education in toxicology in Michigan by having one student from each of the major universities present a research seminar. The third purpose was to educate local high school teachers and their students about the use of science in risk assessment.

**Service at MSU**

Committee assignments

| | |
|---|---|
| 2014-2015 | Search Committee for the founding director of the Center for Research in Ingredient Safety (CRIS) |
| 2014 | Search Committee for faculty in the Department of Pharmacology and Toxicology |

| | |
|---|---|
| 2013-2014 | Chair, Department of Pharmacology and Toxicology Faculty Advisory Committee |
| 2013-Present | Department of Pharmacology and Toxicology Awards Committee |
| 2013-Present | College of Veterinary Medicine Sexual Harassment Liaison |
| 2013 | Chair, Department of Pharmacology and Toxicology Grievance Hearing Board Committee |
| 2012-2013 | Chair, College of Veterinary Medicine Committee on Promotion and Tenure |
| 2011-2014 | Department of Pharmacology and Toxicology Faculty Advisory Committee |
| 2011-2013 | Biomolecular Sciences Gateway Admissions Committee |
| 2011 | Search Committee for faculty in the Department of Pathobiology and Diagnostic Investigation |
| 2011-2015 | College of Veterinary Medicine Committee on Promotion and Tenure |
| 2010-2011 | Department of Pharmacology and Toxicology Diversity Committee |
| 2008-2010 | Chair, College of Veterinary Medicine College Advisory Council |
| 2008-2010 | National Food Safety and Toxicology Center Faculty Advisory Council |
| 2006-2008 | College of Veterinary Medicine College Advisory Council |
| 2007-Present | Department of Pharmacology and Toxicology Graduate Committee |
| 2005-2015 | Comparative Medicine and Integrative Biology Program Admissions and Advisory Committee |
| 2004-2007 | College of Veterinary Medicine Curriculum Committee |
| 2006-2007 | Chair, College of Veterinary Medicine Curriculum Committee |
| 2007 | Search Committee for CVM Associate Dean for Academic Affairs |
| 2006 | Pharmacology and Toxicology Seminar Coordinator |
| 2006 | Search Committee for Dean of College of Veterinary Medicine |
| 2005-2006 | Search Committee for Center for Integrative Toxicology faculty |
| 2005 | Center for Integrative Toxicology Curricular Review Committee |
| 2004-2006 | College of Veterinary Medicine Diversity Committee |
| 2003-2004 | Pharmacology and Toxicology Curriculum Committee |
| 2003-2004 | College of Veterinary Medicine Ad hoc Committee to Review Preclinical Curriculum |
| 2003-2004 | Member, National Food Safey and Toxicology Center Research Task Force |
| 2002-2003 | College of Veterinary Medicine Curriculum Review Task Force |
| 2002-2003 | Search Committee for Pharmacology and Toxicology faculty |
| 2002-2004 | Vice-Chair, College of Veterinary Medicine Graduate Studies and Research Committee |
| 2001-2004 | College of Veterinary Medicine Graduate Studies and Research Committee |

| | |
|---|---|
| 2001-2003 | Pharmacology and Toxicology Safety Committee |
| 2001-2002 | Chair, Search Committee for Pharmacology and Toxicology faculty |
| 2000-2001 | Search Committee for National Food Safety and Toxicology Center faculty |
| 2001 | Search Committee for Interim Chair of Pharmacology and Toxicology |
| 1999-2000 | Chair, College of Veterinary Medicine Diversity Committee |
| 1998 | Search Committee, Pharmacology and Toxicology faculty |
| 1996-1998 | CVM Graduate Grievance Hearing Committee |
| 1999-2000 | Chair, Pharmacology and Toxicology Affirmative Action Committee |
| 1996-1999 | Pharmacology and Toxicology Affirmative Action Committee |

Intramural grant reviews

Michigan Agricultural Experiment Station
Biomedical Science Research Grants
Research Excellence Funding Applications

---

*SOCIETY MEMBERSHIPS:*

| | |
|---|---|
| 2008-Present | International Endotoxin and Innate Immunity Society |
| 1998-2001 | International Endotoxin Society |
| 1996-Present | American Society of Pharmacology and Experimental Therapeutics |
| 1996-Present | Society for Leukocyte Biology |
| 1993-Present | Michigan Regional Chapter of the Society of Toxicology |
| 1987-1989 | North Carolina Chapter of the Society of Toxicology |
| 1987-Present | Society of Toxicology |

---

*TEACHING ACTIVITIES (since 2000):*

| *Year* | *Course* | *Lecture title* | *Type of lecture* | *Audience* |
|---|---|---|---|---|
| 2000-2002 | PHM 819 Principles of Drug Action | Moderator | Didactic | Graduate Students |
| 2000-2009 | PHM 819 Principles of Drug Action | Drug absorption and distribution | Didactic | Graduate Students |

| | | | | |
|---|---|---|---|---|
| 2000-2009 | PHM 819 Principles of Drug Action | Drug excretion | Didactic | Graduate Students |
| 2001, 2003, 2005 | PHM 814 Advanced Principles of Toxicology | Moderator | Didactic | Graduate Students |
| 2001, 2003, 2005 | PHM 814 Advanced Principles of Toxicology | Apoptosis | Didactic | Graduate Students |
| 2003, 2005 | PHM 814 Advanced Principles of Toxicology | Renal Toxicology | Didactic | Graduate Students |
| 2000-2010 | PHM 563 Medical Pharmacology | Nonsteroidal anti-inflammatory drugs | Didactic | Professional Students |
| 2000-2010 | PHM 563 Medical Pharmacology | Other anti-inflammatory drugs – 2 hours | Didactic | Professional Students |
| 2000-Present | PHM 557 Veterinary Toxicology | Chemical Carcinogenesis and Developmental Toxicity | Didactic | Professional Students |
| 2000-Present | HM 573 Integrative Clinical Correlates III | Drug-induced liver injury | Didactic | Professional Students |
| 2001-2003 | PHM 556 Veterinary Pharmacology | Moderator | Didactic | Professional Students |
| 2001-2003 | PHM 556 Veterinary Pharmacology | Introduction to Pharmacology | Didactic | Professional Students |
| 2001-2003 | PHM 556 Veterinary Pharmacology | Nonsteroidal antiinflammatory drugs (2 hrs) | Didactic | Professional Students |
| 2001-2003 | PHM 556 Veterinary Pharmacology | Cancer chemotherapy | Didactic | Professional Students |
| 2001 | HM513 Neurological Domain | Analgesic drugs | Problem-based learning | Professional Students |
| 2001 | OST513 Systems Biology: Neuro-musculoskeletal III | Analgesic drugs | Problem-based learning | Professional Students |
| 2001-2015 | PHM 870 Introduction to Research | Topics related to current research in my lab | Didactic | Graduate students |

| | | | | |
|---|---|---|---|---|
| 2002-2012 | PHM 820 Cellular and Molecular Pharmacology and Toxicology | Pathways to Cell Death | Didactic | Graduate Students |
| 2002-2012 | PHM 820 Cellular and Molecular Pharmacology and Toxicology | Arachidonic acid metabolism and nonsteroidal anti-inflammatory drugs | Didactic | Graduate Students |
| 2003-2005 | PHM 556 Veterinary Pharmacology | Therapy for protozoal infections | Didactic | Professional Students |
| 2003-2005 | PHM 556 Veterinary Pharmacology | Therapy for fungal infections | Didactic | Professional Students |
| 2004 | VM 532 Veterinary Integrated Problem Solving | Case report: Ibuprofen toxicity in a dog<br>2 hours | Problem-based learning | Professional Students |
| 2004-Present | PHM 450 Introduction to Chemical Toxicology | Passage of chemicals across membranes | Didactic | Undergraduate and Graduate Students |
| 2004-Present | PHM 450 Introduction to Chemical Toxicology | Chemical absorption and distribution | Didactic | Undergraduate and Graduate Students |
| 2004-Present | PHM 450 Introduction to Chemical Toxicology | Elimination of chemicals | Didactic | Undergraduate and Graduate Students |
| 2004-Present Even years | PDI 851 Advanced General Pathology | Chemical-induced Cell Injury | Didactic | Graduate Students |
| 2006-Present | Integrated Organ System Pharmacology – Week-long Short Course | Acetaminophen hepatotoxicity | Lecture and Laboratory | Continuing Education and Graduate Students |
| 2007-Present Odd years | PHM 816 Integrative Toxicology: Mechanisms, Pathology and Regulation | Moderator | Didactic | Graduate Students |
| 2007-Present Odd years | PHM 816 Integrative Toxicology: | General Concepts | Didactic | Graduate Students |

| | | | | |
|---|---|---|---|---|
| | Mechanisms, Pathology and Regulation | | | |
| 2007-Present Odd years | PHM 816 Integrative Toxicology: Mechanisms, Pathology and Regulation | Pathways to Cell Death | Didactic | Graduate Students |
| 2017-Present Odd years | PHM 816 Integrative Toxicology: Mechanisms, Pathology and Regulation | Adverse Outcome Pathways | Flipped Learning | Graduate Students |
| 2007 | VM 980 Topics in Toxicology: Pathways to Cell Death | Co-moderator | Lecture/ Seminar | Graduate Students |
| 2007 | VM 980 Topics in Toxicology: Pathways to Cell Death | Introduction to Cell Death | Didactic | Graduate Students |
| 2008 | PDI 891 Topics in Particle Toxicology: Micro- to Nano-particles | Co-moderator | Didactic | Graduate Students |
| 2010-2016 | PHM 563 Medical Pharmacology | Nonsteroidal anti-inflammatory drugs | On-line | Professional Students |
| 2010-2016 | PHM 563 Medical Pharmacology | Other anti-inflammatory drugs – 2 hours | On-line | Professional Students |
| 2010-2016 | PHM 563 Medical Pharmacology | Case reports | In class interactive | Professional Students |
| 2010-2014 | PHM 980 Principles of Drug Action | Drug absorption and distribution | On-line | Graduate Students |
| 2010-2014 | PHM 980 Principles of Drug Action | Drug excretion | On-line | Graduate Students |
| 2010-2014 | PHM 980 Principles of Drug Action | Case reports and research articles – 2 hours | In class interactive | Graduate Students |
| 2010-Present | PHM 557 Veterinary Toxicology | General Concepts in Toxicology | Didactic | Professional Students |

| | | | | |
|---|---|---|---|---|
| 2012-Present | PHM 553 | Pharmacology of hemostasis and hematopoesis – 3 hours | Didactic | Professional Students |
| 2012-Present | PHM 553 | Gastrointestinal pharmacology – 3 hours | Didactic | Professional Students |
| 2014-Present | PHM 802 Cellular, Molecular and Integrated Systems Pharmacology and Toxicology | Arachidonic acid metabolism and nonsteroidal anti-inflammatory drugs – 2 hours | Didactic | Graduate Students |
| 2013-Present | PHM 801 Fundamental Principles of Pharmacology and Toxicology | Drug absorption, drug distribution, drug excretion, special topic – 3 hours | Didactic | Graduate Students |

*GRANT SUPPORT AND CONTRACTS:*

**Current:**

**An assay to predict the potential of drug candidates to cause idiosyncratic, drug-induced liver injury**
NIDDK R01-DK112695
02/01/2017-01/31/2020
PI (R. Roth, Co-PI), 11% effort
$225,000/yr direct costs

**Environmental metals, excitotoxicity and ALS**
NIEHS R01-ES024064
03/01/2015-02/28/2020
Co-Investigator (W. Atchison, PI), 5% effort
$372,000/yr direct costs

**Michigan State University PREP: Increasing underrepresented minority representation in biomedical sciences**
NIGMS R25-GM116761
2017-2020
Co-Investigator (W. Atchison, PI), 5% effort
$373,000/yr direct costs

**<u>Completed</u>:**

**Prediction of idiosyncratic drug-induced liver injury from drug-cytokine interaction in vitro**
Colgate-Palmolive Grant for Alternative Research
05/2014 – 04/2015
PI
$40,000

**Dichotomous roles of thrombin in acetaminophen hepatotoxicity**
NIDDK R01-087886
2010-2014
Co-Investigator (R. Roth, PI), 5% effort
$225,000/yr direct costs

**Environmental, Microbial and Mammalian Biomolecular Responses to AhR Ligands**
NIEHS P01 ES04911
04/01/2006-03/31/2012
PI of the program project: N. Kaminski
My role: PI of Project 4, 17% effort: “Influence of Ah Receptor Ligands on Inflammatory Responses: Consequences for Tissue Injury and Gene Expression”
$200,000/yr direct costs

**Neutrophils and Hepatotoxicity**
NIEHS R01 004139
04/03/06-03/31/12
Co-Investigator (PI, R.Roth), 15% effort
$267,000/yr direct costs

**Inflammation and Drug Idiosyncrasy**
NIDDK R01 061315
2008-2012
Co-Investigator (R. Roth, PI), 5% effort

$225,000/yr direct costs

**Gene Expression in Drug-inflammation Models as Predictive of Idiosyncratic ADRs**
NIGMS R21 075865
09/19/2005-09/18/2009
Principal Investigator, 15% effort
$250,000/yr direct costs

**Inflammation/Drug Interaction: Towards Validation of an Animal Model for Idiosyncratic Drug-induced Liver Injury: A Collaborative Research Proposal**
Pfizer, Inc.
01/2006-12/2007
Principal Investigator, 10% effort
$130,000/year direct costs

**Health Hazards from Groundwater Contamination**
NIEHS P01 ES04911
04/01/2000-03/31/2006
PI of the program project: L.J. Fischer
My role: PI of Project 6 (20% effort): Activation of AhR-Dependent and AhR-Independent Signaling Cascades in PCB-Induced Immune Dysfunction
$100,000/yr direct costs

**Health Hazards from Groundwater Contamination**
NIEHS P01 ES04911
04/01/2000-03/31/2006
PI of the program project: L.J. Fischer
My role: Co-Director (5% effort) of Remediation Product Evaluation Core
$100,000/yr direct costs

**SAMe Inhibits Inflammatory-mediated Enhanced Toxicity**
NIH/NIAAAA014134
2002-2004
Co-Investigator (J. Maddox, PI), 10% effort
$50,000/yr direct costs

**Modeling Inflammation-drug Interactions in Vitro**
Pfizer Corp.
01/01/2004-12/31/2004

Co-Investigator (R. Roth, PI), 5% effort
$120,000/yr direct costs

**Inflammation as a Determinant of Susceptibility to Drug Toxicity: Toward an Animal Model of Idiosyncratic Hepatotoxicity**
Abbott Laboratories
01/01/2004-12/31/2004
Co-Investigator (R. Roth, PI), 5% effort
$94,000 direct costs

**Endotoxin Enhancement of Hepatotoxicity: Role of $PGD_2$**
NIH/NIEHS R01 ES08789
1998-2003
Principal Investigator, 20% effort
$192,000/yr direct costs

**Neutrophils and Hepatotoxicity**
NIEHS R01 04139
1998-2003
Co-Investigator (R. Roth, PI), 10% effort
$200,000/year direct costs

**Distal Events in the Hepatotoxicity of Endotoxin**
NIH/NIDDK R01 50728
1996-2001
Co-Investigator (R. Roth, PI), 30% effort
$128,000/yr direct costs

**Effect of $O_3$/Endotoxin Coexposure on Airway Epithelium**
NHLBI R01
1997-2001
Co-Investigator (J. Harkema, PI), 5% effort
$170,000/yr direct costs

**Inflammation as a Determinant of Susceptibility to Drug Toxicity: Toward an Animal Model of Drug Idiosyncrasy**
Pharmacy & Upjohn Collaborative Agreement
2001-2003

Co-Investigator (R. Roth, PI), 5% effort
$113,000 direct costs

**Health Hazards from Groundwater Contamination**
NIEHS P01 ES04911
1988-2000
PI of the program project: L.J. Fischer
My role: PI of Project 5A (20%): Mechanisms and Consequences of Neutrophil Activation by Hazardous Chemicals
$100,000/yr direct costs

**Health Hazards from Groundwater Contamination**
NIEHS P01 ES04911
1995-2000
PI of the program project: L.J. Fischer
My role: Co-Director of Remediation Product Evaluation Core, 5% effort
$100,000/yr direct costs

---

*PATENTS:*

2017: Provisional Application for Patent; Docket No. MSS-014.60; In Vitro Methods for Classifying Drugs According to Their Potential to Cause Liver Cell Injury

---

*PARTICIPATION IN TRAINING GRANTS:*

Research Education Program to Increase the Number and Diversity of Researchers in Health-related Research
Environmental and Integrative Toxicological Sciences
Research Training Program for Veterinary Students
Short-term Research Training Program for Veterinary Students

---

*STUDENTS AND POSTDOCTORAL TRAINEES:*

**Graduate Students:**

*Primary advisor to:*

| | |
|---|---|
| **Name:** | Ashley Maiuri |
| **Degree/Year of Graduation:** | Ph.D. 2015, Pharmacology and Toxicology/Environmental Toxicology |
| **Thesis Title:** | In vitro Mechanisms of Cytotoxic Interaction of Cytokines and Drugs Associated with Idiosyncratic, Drug-induced Liver Injury |
| **Current Position:** | Toxicology Consultant, Integrated Nonclinical Development Solutions Inc, Ann Arbor, MI |

| | |
|---|---|
| **Name:** | Aaron Fullerton |
| **Degree/Year of Graduation:** | PhD, 2013, Pharmacology and Toxicology/Environmental Toxicology |
| **Thesis Title:** | Influence of Dioxin on T-cell Mediated Liver Injury Injury |
| **Current Position:** | Associate Scientist, Investigative Toxicology, Genentech, San Francisco, CA |

| | |
|---|---|
| **Name:** | Kevin Beggs (co-advisor) |
| **Degree/Year of Graduation:** | PhD, 2013, Pharmacology and Toxicology/Environmental Toxicology |
| **Thesis Title:** | Molecular Mechanisms of Hepatocellular Apoptosis Induced by Trovafloxacin-Tumor Necrosis Factor-Alpha Interaction |
| **Current Position:** | Postdoctoral Fellow, University of Kansas Medical Center |

| | |
|---|---|
| **Name:** | Kyle Poulsen (co-advisor) |
| **Degree/Year of Graduation:** | PhD, 2013, Pharmacology and Toxicology/Environmental Toxicology |
| **Thesis Title:** | Molecular Mechanisms of Trovafloxacin Potentiation of Lipopolysaccharide-induced Tumor Necrosis Factor Release from RAW 264.7 Cells |
| **Current Position:** | Postdoctoral Fellow, Cleveland Clinic Lerner Research Institute |

| | |
|---|---|
| **Name:** | Jingtao Lu |
| **Degree/Year of Graduation:** | PhD, 2012, Biochemistry and Molecular Biology/Environmental Toxicology |
| **Thesis Title:** | Mechanisms of Amiodarone/Lipopolysaccharide-induced Liver Injury: A Model of Idiosyncratic, Drug-induced Hepatotoxicity |
| **Current Position:** | Postdoctoral Fellow, ORISE, US Environmental Protection Agency, Research Triangle Park, NC |

| | |
|---|---|
| **Name:** | Erica Sparkenbaugh (coadvisor) |
| **Degree/Year of Graduation:** | PhD, 2011, Pharmacology and Toxicology/Environmental Toxicology |
| **Thesis Title:** | The Role of Hypoxia, Neutrophil Elastase and HIF-1alpha in Hepatocellular Injury |
| **Current Position:** | Postdoctoral Fellow, University of North Carolina |

| | |
|---|---|
| **Name:** | Christine Dugan |
| **Degree/Year of Graduation:** | PhD, 2010, Cell and Molecular Biology/Environmental Toxicology |
| **Thesis Title:** | A Mouse Model of Halothane Hepatitis Based on Human Risk Factors: A Sexaually Dimorphic Immune-mediated Mechanism |
| **Current Position:** | Internal Medicine Resident, MSU Kalamazoo Center for Medical Studies Borgess/Bronson Hospitals |

| | |
|---|---|
| **Name:** | Wei Zou (coadvisor) |
| **Degree/Year of Graduation:** | PhD, 2010, Microbiology and Molecular Genetics/Environmental Toxicology |
| **Thesis Title:** | Mechanisms of Sulindac/LPS-induced Liver Injury in Rats: An Animal Model of Idiosyncratic Hepatotoxicity |
| **Current Position:** | Scientist, ProMetic, Washington, DC |

| | |
|---|---|
| **Name:** | Steven Bezdecny |
| **Degree/Year of Graduation:** | PhD, 2006, Pharmacology and Toxicology/Environmental Toxicology |
| **Thesis Title:** | Signal Transduction Pathways Involved in the Upregulation of Cyclooxygenase-2 by 2,2',4,4'-Tetrachlorobiphenyl |
| **Current Position:** | High School Teacher, Essex County, NJ |

**Name:** Shawn Kinser
**Degree/Year of Graduation:** PhD, 2001, Pharmacology and Toxicology
**Thesis Title:** Mechanisms of Enhanced Allyl Alcohol Hepatotoxicity by Endotoxin
**Current Position:** Dentist, Flat River Family Dentistry, Greenville, MI

**Name:** Jesus Olivero-Verbel
**Degree/Year of Graduation:** PhD, 1999, Pharmacology and Toxicology
**Thesis Title:** Activation of Phospholipase $A_2$ by Polychlorinated Biphenyls (PCBs) and Other Chlorinated Compounds
**Current Position:** Vice Chancellor of Research, Universidad de Cartagena, Cartagena, Colombia, South America

**Name:** Rosie Sneed, DVM
**Degree/Year of Graduation:** PhD, 2000, Pharmacology and Toxicology
**Thesis Title:** The Role of the Innate Immune System in the LPS-Induced Potentiation of Allyl Alcohol Hepatotoxicity
**Current Position:** Associate Professor, University of the District of Columbia, Washington, DC

*Thesis committee member for:*

| Name | Program | Years |
|---|---|---|
| Omar Kana | Pharmacology and Toxicology | 2019-Present |
| Jeremy Gingrich | Pharmacology and Toxicology | 2018-Present |
| Katherine Roth | Pharmacology and Toxicology | 2015 - Present |
| Mónica Rios-Cabanillas | Comparative Medicine and Integrative Biology | 2015 - Present |
| Duanghathai Wiwatratana | Comparative Medicine and Integrative Biology | 2015 - Present |
| Phillip Brooks | Comparative Medicine and Integrative Biology | 2014 - 2017 |

| | | |
|---|---|---|
| Alexandra Colón-Rodriguez | Comparative Medicine and Integrative Biology | 2013 - 2017 |
| Alexandra Turley | Pharmacology and Toxicology | 2013 - 2018 |
| Bronlyn Wassink | Statistics and Probability | 2013 - 2016 |
| Erica Clarke | Food Science | 2012 - 2015 |
| Lauren Azevedo | Pharmacology and Toxicology; dual degree student in Osteopathic Medicine | 2012 – 2013 |
| Heidi Hannon | Comparative Medicine and Integrative Biology | 2012 – 2017 |
| Shawna D'Ingillo | Pharmacology and Toxicology | 2011 – 2013 |
| Kazuhisa Miyakawa, BvSc | Pathobiology and Diagnostic Investigation | 2010 – 2015 |
| Brenna Flannery | Food Science | 2009 – 2012 |
| Peer Karmaus | Biochemisty and Molecular Biology | 2007 – 2012 |
| Aaron McBride | Cell and Molecular Biology | 2008 – 2009 |
| Daher Ibrahim Aibo, BvSc | Comparative Medicine and Integrative Biology | 2007 – 2009 |
| Chidozie Amuzie, BvSc | Comparative Medicine and Integrative Biology | 2005 – 2008 |
| Dina Shnaider | Pharmacology and Toxicology | 2004 – 2008 |
| Nasr Aref | Large Animal Clinical Sciences | 2004 – 2008 |
| Hoon Yoo | Fisheries and Wildlife | 2004 – 2008 |
| Patrick Shaw | Pharmacology and Toxicology | 2004 – 2008 |
| Cora Fong | Biochemistry and Molecular Biology | 2003 – 2007 |
| Gautham Rao | Pharmacology and Toxicology | 2002 – 2005 |
| Stacey Wilder | Environmental Engineering | 2001 – 2003 |
| Andrea Satoh | Environmental Engineering | 2000 – 2002 (MS)<br>2003 – 2008 (PhD) |
| John Buchweitz | Pharmacology and Toxicology | 1999 – 2001 |
| James Luyendyk | Pharmacology and Toxicology | 1999 – 2004 |
| Aimen Farraj | Pharmacology and Toxicology | 1999 – 2003 |
| Steven Yee | Pharmacology and Toxicology | 1998 – 2003 |
| Min Kim | Human Nutrition | 1998 – 2002 |
| Robert Molner | Surgery | 1998 – 2000 |
| Rebecca Marcus | Pharmacology and Toxicology | 1998 – 2000 |
| Xinguang Li | Pharmacology and Toxicology | 1996 – 2000 |
| Frederic Moulin, DVM | Pharmacology and Toxicology | 1994 – 1999 |
| Marc Bailie, DVM | Pharmacology and Toxicology | 1990 - 1994 |

**Postdoctoral Trainees:**

Rachel Murphy, PhD 2017 - 2018
Jordan Bailey, PhD 2016 - 2018
Rohit Singhal, PhD 2009 - 2012
Jesus Olivero, PhD 2006 - 2008
Present position: Vice President for Research, Universidad de Cartagena, Colombia, South America
Sachin Devi, PhD 2005-2007
Present position: Professor, LECOM School of Pharmacy, Sarasota, FL
Alan Brown, PhD 1993-1996; Supported by NRSA from NIH
Present position: Preclinical Safety CVM, Novartis Institutes for BioMedical Research Inc., Cambridge, MA
Patricia Tithof, PhD, DVM 1993-1996
Present position: Senior Lecturer, Berry College, Mount Berry, GA

**Undergraduate, Professional and High School Students:**

Anna Breier 2014-2015
Gurpreet Kaur 2014
Robert Parkins, III 2013
Ryan Albee 2010-2013
Mitchell Nothem 2010; ASPET SURF
Melanie Seymour 2009; DVM student
Sarah Thomas 2009; ASPET SURF
Allen MacDonald 2008-2010
Emilie Evenson 2007-2008
Peer Karmaus 2006
Nicole Chalmers 2005; ASPET SURF
Theresa Eagle 2004-2006; ASPET SURF
Alison Domzalski 2002-2003
Brook Woolley 2002
Natasha Tasheva 2001-2002
Ali Mahajerin 1996-1998; Professorial Assistant

| | |
|---|---|
| Melinda Baker | 1998-2000; Professorial Assistant |
| Kirsten Reuhle | 1998 |
| Wendy Holdan | 1998 |
| Sarah Kessel | 1995-1997 |
| Liz Schiamburg | 1995; High School Honors Summer Program |
| Simi VanCise | 1994-1995 |
| Maria Colligan | 1994 |

---

*AWARDS AND HONORS WON BY TRAINEES:*

**Graduate Students:**

Shawn Kinser, 2000: SOT Graduate Student Advisory Council, member
Shawn Kinser, 2000: SOT Graduate Student Travel Award
Steve Bezdecny, 2005: SOT Graduate Student Travel Award
Christine Dugan, 2007: Council of Graduate Students Travel Award
Christine Dugan, 2008: Graduate Student Award from the SOT Toxicology and Exploratory Pathology Specialty Section
Aaron Fullerton, 2008: Young Investigator Award from the International Endotoxin and Innate Immune Society
Wei Zou, 2008: SOT Graduate Student Travel Award
Christine Dugan, 2009: Trainee Travel Award to attend "Pattern Receptors ad Innate Immune Signaling Pathways in Liver Diseases"
Christine Dugan, 2009: Graduate Student Poster Award, 1st place, Michigan SOT
Wei Zou, 2009; Graduate Student Best Abstract Award, 2nd place, Division of Toxicology, ASPET
Aaron Fullerton, 2009: Best Poster Award, 2nd place, Environmental Health Sciences Regional Showcase of Fellows
Christine Dugan, 2010: SOT Graduate Student Travel Award funded by Millennium Pharmaceuticals
Christine Dugan, 2010: Suzan Jean Snyder Award, MSU College of Osteopathic Medicine
Christine Dugan, 2010: Travel Award to attend the combined annual meeting of the Central Society for Clinical Research and the Midwestern Section of the American Federation for Medical Research
Christine Dugan, 2010: Dissertation Completion Fellowship
Jingtao Lu, 2010: SOT Graduate Student Travel Award
Kyle Poulsen, 2012: First Runner Up, Poster Competition, Michigan Regional Chapter of the SOT
Aaron Fullerton, 2010: Regional Chapter Graduate Student Representative
Aaron Fullerton, 2010: Regional Chapter Graduate Student Representative Travel Award

Aaron Fullerton, 2011: SOT Graduate Student Travel Award

Aaron Fullerton, 2011: Selected as one of three graduate students to give an oral platform presentation at the Michigan SOT 2011 Spring meeting at MPI Research, "Immunotoxicology and Safety Assessment—21st Century Advances and Challenges"

Jingtao Lu, 2011: Graduate Student Travel Award from the Center for Integrative Toxicology

Jingtao Lu, 2011: Graduate Student Travel Award from the SOT Comparative and Veterinary Specialty Section of SOT

Jingtao Lu, 2011: Dissertation Completion Fellowship

Aaron Fullerton, 2012: Dissertation Completion Fellowship

Aaron Fullerton, 2012: Graduate Student Poster Award, 1st place, Michigan SOT

Kyle Poulsen, 2013: Graduate Student Travel Award from the SOT

Kyle Poulsen, 2013: Carl C. Smith Award for Meritorious Research Finalist and Honorable Mention, Mechanisms Specialty Section, SOT

Ashley Maiuri, 2013: Center for Integrative Toxicology Graduate Student Travel Award (to travel to the SOT annual meeting)

Ashley Maiuri, 2013: SOT Graduate Student Travel Award

Ashley Maiuri, 2014: Center for Integrative Toxicology Research Travel Award (to spend time at the Hamner Institute in NC)

Ashley Maiuri, 2014: Graduate Student Travel Award from the In Vitro and Alternative Methods Specialty Section, SOT

Ashley Maiuri, 2014: Center for Integrative Toxicology Graduate Student Travel Award (to travel to the SOT annual meeting)

Ashley Maiuri, 2016: Graduate Student Travel Award from the In Vitro and Alternative Methods Specialty Section, SOT

**<u>Postdoctoral Trainees</u>:**

Francis Tukov, D.V.M., Ph.D.: 2005 Colgate-Palmolive Postdooctoral Fellowship Award in *In Vitro* Toxicology (SOT)

Rohit Singhal, Ph.D., 2010: Postdoctoral Trainee Travel award, SOT Mechanisms Specialty Section

**<u>Undergraduate Students</u>:**

Alison Domzalski, 2001: Award for poster presentation at the MSU Undergraduate

Research Forum
Theresa Eagle, 2005: SOT Pfizer Undergraduate Student Travel Award

**Employee:**

Sandra Newport, research assistant, 2005: Staff Poster Award, 1st place, Michigan SOT

---

*INVITED TALKS:*

2018 The role of cytokines in drug-induced liver injury. University of Georgia Integrated Toxicology Program, Athens, GA

2017 Drug-cytokine interaction in idiosyncratic hepatotoxicity, World Preclinical Congress, Predicting Drug Toxicity, Boston, MA

2017 The role of cytokines in drug-induced liver injury, American College of Toxicology 38th Annual Meeting, Palm Springs, CA

2017 Career choices in Toxicology…and the future…., Toxicology Inaugural Weekend Workshop, Ames Iowa

2017 Mechanisms of cell death from interaction of cytokines with drugs that cause idiosyncratic liver injury, 44th Annual Meeting of the Japanese Society of Toxicology

2015 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin augments hepatotoxicity in a mouse model of immune-mediated liver injury, International Seminar on Cell Death and Inflammation, University de Cartagena, Cartagena, Colombia, South America

2015 Cell Death, International Seminar on Cell Death and Inflammation, University de Cartagena, Cartagena, Colombia, South America

2015 General Concepts in Toxicology, International Seminar on Cell Death and Inflammation, University de Cartagena, Cartagena, Colombia, South America

2014 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin augments hepatotoxicity in a mouse model of immune-mediated liver injury, Andrews University, Berrien Springs, MI

2013 Inflammatory stress and drug-induced liver injury, Environmental Mutagenesis and Genomics Society Annual Meeting, Monterey, CA

2012 Sex and inflammation in idiosyncratic, drug-induced liver injury, 11th Annual World Pharma Congress, Philadelphia, PA

2011 Sex and inflammation in idiosyncratic, drug-induced liver injury, The Hamner - UNC Institute for Drug Safety Sciences, Research Triangle Park, NC

2010 Idiosyncratic liver injury from halothane: New thoughts on an old drug, 2010 Kenneth E. Moore Distinguished Alumna Lecture, Michigan State University, East Lansing, MI

2010 Microbial products enhance xenobiotic-induced liver injury, Health Consequences from Xenobiotic-Gut Microbiome-Host Interactions, Research Triangle Park, NC

2010 Acetaminophen toxicity, Environmental Studies 28: Global Environmental Health, Dartmouth Medical School, Hanover, NH

2010 Idiosyncratic Drug-induced Liver Injury: The Inflammatory Stress Hypothesis and Animal Models, Dartmouth Medical School, Hanover, NH

2009 Multiple modes of action an inflammatory stress-drug interaction model of idiosyncratic liver injury, Drug Metabolism Gordon Conference, Holderness, NH

2009 Inflammation as a susceptibility factor for hepatotoxicity: developing models of drug-induced idiosyncratic reactions, University of North Carolina Curriculum in Toxicology, First Annual Postdoctoral Retreat, Guest Speaker, Chapel Hill, NC

2008 Idiosyncratic drug-induced liver injury and inflammatory stress, Experimental Biology Annual Meeting, San Diego, CA

2008 Hepatocyte systems for understanding mechanisms of drug-inflammation interactions that lead to liver injury, Annual Meeting of the Society of Toxicologic Pathologists, San Francisco, CA

2007 Progression and sensitivity factors in “intrinsic” and “idiosyncratic” drug-induced liver injury, Drug Metabolism Gordon Conference, Holderness, NH

2006 The contribution of Kupffer cell-derived mediators to acute hepatotoxicity, Astra

Zeneca, Alderly Park, England

2006 The contribution of Kupffer cell-derived mediators to acute hepatotoxicity, Society of Toxicology Annual Meeting, San Diego, CA

2006 Inflammatory stress and susceptibility to drug-induced liver injury: Exploration of hepatic gene expression as predictive markers, Predictive Models of Drug Safety Assessment, NIH, Bethesda, MD

2004 Upregulation of Cyclooxygenase-2 in Neutrophils by Polychlorinated Biphenyls, Conference on Applying Molecular Technology Methods to Characterize and Reduce Risks to Humans and the Ecosystem, Seattle, WA

2004 Inflammation and Susceptibility to Chemical-induced Hepatotoxicity: Potential Implications for Drug-induced Idiosyncratic Responses, Department of Pharmacology, University of Toledo, Toledo, OH

2004 Inflammation and Susceptibility to Chemical-induced Hepatotoxicity, School of Public Health, University of Michigan, Ann Arbor, MI

2002 Does bioremediation reduce the biological activity of PCBs? Conference on Bioremediation and Biodegradation: Current Advances in Reducing Toxicity, Exposure and Environmental Consequences", Pacific Grove, CA

2001 Inflammation-mediated Potentiation of Hepatotoxicity and the Potential Implications for Drug-induced Idiosyncratic Responses, Pfizer Global Research, Ann Arbor, MI

2001 Inflammation Augments Acute Hepatotoxicity Caused by Mycotoxins, Gordon Research Conference on Mycotoxins and Phycotoxins, Williams College, MA

2000 Neutrophil Phospholipase $A_2$ as a Target for the Action of Polychlorinated Biphenyls, Environmental Toxicology Program, University of Illinois at Urbana-Champagne

2000 The Role of Phospholipase $A_2$ in Activation of Neutrophils by Polychlorinated Biphenyls, Chemical Industries Institute of Toxicology, Research Triangle Park, NC

2000 Cyclooxygenase-2 in Inflammation-mediated Modulation of Allyl Alcohol-induced, Biomedical Sciences Program, Marshall University

1999 Inflammation-mediated Modulation of Chemically Induced Hepatotoxicity,

Environmental Toxicology Program, University of Texas Medical Branch at Galveston

1999 Inflammation-mediated Modulation of Chemically Induced Hepatotoxicity, Medical Technology Program, Michigan State University

1999 Inflammation During Chemically Induced Tissue Injury: Friend or Foe?, University of Cayey, Cayey, Puerto Rico

1998 Inflammation-mediated Modulation of Chemically Induced Hepatotoxicity, Department of Pharmaceutical Sciences, Wayne State University

1997 Inflammation-mediated Modulation of Chemically Induced Hepatotoxicity, Toxicology Program, University of Michigan

1997 Mechanisms of Activation of Neutrophils by Polychlorinated Biphenyls, Biological Actions of Non-Coplanar Polychlorinated Biphenyls, Symposium, Annual Meeting of the Society of Toxicology, Cincinnati, OH

1996 Signalling Mechanisms in Activation of Neutrophils by Xenobiotics, Symposium, World Congress on In Vitro Biology, San Francisco, CA

1995 Mechanisms of Inflammatory Liver Injury: Adhesion Molecules and Cytotoxicity of Neutrophils, Symposium, Annual Meeting of the Society of Toxicology, Baltimore, MD

1994 Department of Biology, Western Michigan University

1994 The Role of Cell Mediators in the Toxic Response, Session-in-Depth, Tissue Culture Association Meeting, Research Triangle Park, NC

1994 Studies on Drug Metabolism and Toxicity at Various Levels of Organization in the Liver, Short Course, International Society for the Study of Xenobiotics, Raleigh, NC

1989 North Carolina Chapter of the Society of Toxicology

1985 New Investigators' Colloquium, Annual Meeting of the Society of Toxicology, San Diego, CA

*PUBLICATIONS*

**Articles in Refereed Journals:**

1) Maiuri AR, Wassink B, Turkus JD, Breier AB, Lansdell T, Kaur G, Hession SL, Ganey PE, Roth RA. Synergistic cytotoxicity from drugs and cytokines in vitro as an approach to classify drugs according to their potential to cause idiosyncratic hepatotoxicity: A proof-of-concept study. J Pharmacol Exp Ther, 2017 362(3): 459-473. doi: 10.1124/jpet.117.242354. Epub 2017 Jul 7. PMID: 28687704

2) Roth RA, Maiuri AR, Ganey PE. Idiosyncratic drug-inducedd liver injury: Is drug-cytokine interaction the linchpin? J Pharmacol Exp Ther, 2017 360(2): 461-470. doi: 10.1124/jpet.116.237578. Epub 2016 Nov 15. PMID 28104833

3) Maiuri AR, Breier AB, Turkus JD, Ganey PE, Roth RA. Calcium contributes to the cytotoxic interaction between diclofenac and cytokines. Tox Sci 149(2): 372-384, 2016. doi: 10.1093/toxsci/kfv249. Epub 2015 Nov 24.PMID: 26609140

4) Miyakawa K, Joshi N, Sullivan BP, Albee R, Brandenberger C, Jaeschke H, McGill MR, Scott MA, Ganey PE, Luyendyk JP, Roth RA. Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice. Blood, 2015, Oct 8;126(15):1835-43. doi: 10.1182/blood-2014-09-598656. Epub 2015 Jul 15. PMID: 26179083.

5) Maiuri AR, Breier AB, Gora LF, Parkins RV, Ganey PE, Roth RA. Cytotoxic synergy between cytokines and NSAIDs associated with idiosyncratic hepatotoxicity is driven by mitogen-activated protein kinases. Tox Sci 146(2): 265-280, 2015; PMID: 25953702

6) Miyakawa K, Albee R, Letzig LG, Lehner AF, Scott M, Buchweitz JP, James LP, Ganey PE, Roth RA. A cytochrome P450-independent mechanism of acetaminophen-induced hepatocellular injury in cultured mouse hepatocytes. J Pharmacol Exp Ther, 354(2): 230-237, 2015; PMID: 26065700. *Highlighted paper.*

7) Beggs KM, Maiuri AR, Fullerton AM, Poulsen KL, Breier AB, Ganey PE, Roth RA. Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related. Toxicology 331: 35-46, 2015, PMID:25748550.

8) Poulsen KL, Olivero-Verbel J, Beggs KM, Ganey PE, Roth RA. Trovafloxacin enhances LPS-stimulated production of TNF by macrophages: role of the DNA damage response. J Pharmacol Exp Ther 350(1): 164-170, 2014, PMID 24817034

9) Poulsen KL, Albee RP, Ganey PE, Roth RA. Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires ERK and JNK. J Pharmacol Exp Ther 349(2): 185-191, 2014, PMID 24525298

10) Beggs KM, Fullerton AM, Miyakawa K, Ganey PE, Roth RA. Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction. Toxicol Sci 137(1): 91-101, 2014, PMID 24097668.

11) Fullerton AM, Roth RA, Ganey PE. Pretreatment with TCDD exacerbates liver injury from concanavalin A: critical role for NK cells. Toxicol Sci 136(1): 72-85, 2013; doi: 10.1093/toxsci/kft174; PMID: 23164664

12) Lu J, Roth RA, Malle E, Ganey PE. Roles of the hemostatic system and neutrophils in liver injury from coexposure to amiodarone and lipopolysaccharide. Toxicol Sci 136(1): 51-62, 2013; doi: 10.1093/toxsci/kft170; PMID: 23912913

13) Fullerton AM, Roth RA, Ganey PE. 2,3,7,8-TCDD enhances the sensitivity of mice to concanavalin A immune-mediated liver injury. Toxicol Appl Pharmacol 266: 317-327, 2013. PMID 23164664

14) Lu J, Miyakawa K, Roth RA, Ganey PE. Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress. Toxicol Sci 131(1):164-178, 2013. PMID 23042730

15) Coen MP, Rademacher PM, Zou W, Scott M, Ganey P, Roth R, Nelson SD. Comparative NMR-based metabonomic investigation of the metabolic phenotype associated with tienilic acid and tienilic acid isomer. Chem Res Toxicol 25(11): 2412-2422, 2012. PMID: 23013248

16) Singhal R, Ganey PE, Roth RA. Complement activation in acetaminophen-induced liver injury in mice. J Pharmacol Exp Ther 341(2): 377-385, 2012. PMID: 22319198

17) Sparkenbaugh EM, Ganey PE, Roth RA. Hypoxia sensitization of hepatocytes to neutrophil elastase-mediated cell death depends on MAPKs and HIF-1α. Am J Physiol Gastrointest Liver Physiol 302(7): G748-57, 2012. PMID: 22223132

18) Zou W, Roth RA, Younis HS, Malle E, Ganey PE. Neutrophil-cytokine interactions in a rat model of sulindac-induced idiosyncratic liver injury. Toxicology 290(2-3):279-286, 2011.

19) Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci Jan 125(1): 126-133, 2012 doi: 10.1093/toxsci/kfr266

20) Sparkenbaugh EM, Saini Y, Greenwood KK, Lapres JJ, Luyendyk JP, Copple BL, Maddox JF, Ganey PE, Roth RA. The role of hypoxia inducible factor-1 alpha (HIF-1{alpha}) in acetaminophen hepatotoxicity. J Pharmacol Exp Ther. 338(2):492-502, 2011. PMID: 21576378

21) Olivero-Verbel J, Roth RA, Ganey PE. Dioxin alters inflammatory responses to lipopolysaccharide. Toxicol Environ Chem. 93(6): 1180-1194, 2011. http://www.tandfonline.com/doi/abs/10.1080/02772248.2011.577554

22) Dugan CM, Fullerton AM, Roth RA, Ganey PE. Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis. Toxicol Sci 120(2):507-518, 2011.

23) Liguori MJ, Ditewig AC, Maddox JF, Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Waring JF, Ganey PE, Roth RA, Blomme EA. Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: trovafloxacin as an example. Int J Mol Sci 11(11): 4697-4714, 2010.

24) Shaw PJ, Ganey PE, Roth RA. Idiosyncratic, drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci, 118(1): 7-18, 2010.

25) Zou W, Roth RA, Younis HS, Burgoon LD, Ganey PE. Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment. Toxicology, 272(1-3):32-8, 2010.

26) Dugan CM, MacDonald AE, Roth RA, Ganey PE. A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther, May:333(2):364-72, 2010.

27) Aibo DI, Birmingham NP, Lewandowski R, Maddox JF, Roth RA, Ganey PE, Wagner JG, Harkema JR. Acute exposure to ozone exacerbates acetaminophen-induced liver injury in mice. Toxicol Sci, May;115(1):267-85, 2010.

28) Roth RA, Ganey PE. Intrinsic vs idiosyncratic drug-induced hepatotoxicity -- Two villains or one? J Pharmacol Exp Ther, Mar;332(3):692-697, 2010.

29) Maddox JF, Amuzie CJ, Li M, Newport SW, Sparkenbaugh E, Cuff CF, Pestka JJ, Cantor GH, Roth RA, Ganey PE. Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol and Environ Health, Part A. 73 (1), 58-73, 2009. PMID: 19953420

30) Zou W, Beggs KM, Sparkenbaugh EM, Jones AD, Younis HS, Roth RA, Ganey PE. Sulindac metabolism and synergy with tumor necrosis factor-$\alpha$ in a drug-inflammation interaction model of idiosyncratic liver injury. J Pharmacol Exp Ther. 331(1), 114–121, 2009. PMID: 19638570

31) Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, Ganey PE. Hepatotoxic interaction of sulindac with lipopolysaccharide: Role of the hemostatic system. Toxicol Sci. 108, 184-193, 2009. PMID: 19074762

32) Shaw PJ, Beggs KM, Sparkenbaugh EM, Dugan CM, Ganey PE, Roth RA. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol Sci. Oct;111(2):288-301, 2009. PMID: 19638433

33) Shaw PJ, Fullerton AM, Scott MA, Ganey PE, Roth RA. The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. Toxicol Appl Pharmacol. 236(3), 293-300, 2009.

34) Shaw P, Ganey PE, Roth RA. Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. J Pharmacol Exp Ther. 330(1):72-78, 2009.

35) Shaw PJ, Ditewig AC, Waring JF, Liguori MJ, Blomme EA, Ganey PE, Roth RA. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci. 107(1), 270-280, 2009.

36) Shaw PJ, Ganey PE, Roth RA. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J Pharmacol Exp Ther. 328(1), 62-68, 2009.

37) Deng X, Liguori MJ, Sparkenbaugh EM, Waring JF, Blomme EA, Ganey PE, Roth RA. Gene expression profiles in livers from diclofenac-treated rats reveal intestinal bacteria-dependent and -independent pathways associated with liver injury. J Pharmacol Exp Ther. 327(3), 634-644, 2008. PMID: 18801949

38) Deng X, Lu J, Lehman-McKeeman LD, Malle E, Crandall DL, Ganey, PE, Roth RA. p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine. J Pharmacol Exp Ther. 326(1), 144-152, 2008.

39) Ganey PE*, Luyendyk JP*, Newport SW, Eagle TM, Maddox JF, Mackman N, Roth RA. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology 46(4), 1177-1186, 2007. **shared co-first author responsibility*

40) Tukov FF, Luyendyk JP, Ganey PE, Roth RA. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 100(1), 267-280, 2007.

41) Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci. 100(1), 259-266, 2007.

42) Bezdecny SA, Karmaus P, Roth RA, Ganey PE. 2,2',4,4'-Tetrachlorobiphenyl upregulates cyclooxygenase-2 in HL-60 cells via p38 mitogen-activated protein kinase and NF-kappaB. Toxicol Appl Pharmacol 221(3), 285-294, 2007.

43) Deng X, Luyendyk JP, Zou W, Lu J, Malle E, Ganey PE, Roth RA. Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 322(2), 852-861, 2007.

44) Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 96, 2-15, 2007.

45) Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, Maddox JF, Ganey PE, Roth RA. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 319(3), 1191-1199, 2006.

46) Copple BL, Roth RA, Ganey PE. Anticoagulation and inhibition of nitric oxide synthase influence hepatic hypoxia after monocrotaline exposure. Toxicology 225(2-3), 128-137, 2006.

47) Tukov FF, Maddox JF, Amacher DE, Bobrowski WF, Roth RA, Ganey PE. Modeling inflammation-drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system. Toxicol In Vitro 20(8), 1488-99, 2006.

48) Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor GH, Maddox JF, Ganey PE, Roth RA. Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug idiosyncrasy rat model: Comparison with famotidine. Toxicol Sci 90(2), 569-585, 2006.

49) Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EA, Roth RA. Microarray analysis of LPS potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 316, 1080-1087, 2006.

50) Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor GH, Deng X, Maddox JF, Ganey PE, Roth RA. Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. J Pharmacol Exp Ther 317, 635-643, 2006.

51) Maddox JF, Luyendyk JP, Cosma GN, Breau AP, Bible RH Jr, Harrigan GG, Goodacre R, Ganey PE, Cantor GH, Cockerell GL, Roth RA. Metabonomic evaluation of idiosyncrasy-like liver injury in rats cotreated with ranitidine and lipopolysaccharide. Toxicol Appl Pharmacol 212, 35-44, 2006.

52) Bezdecny SA, Roth RA, Ganey PE. Effects of 2,2',4,4'-tetrachlorobiphenyl on granulocytic HL-60 cell function and expression of cyclooxygenase-2. Toxicol Sci 84, 328-334, 2005.

53) Luyendyk JP, Shaw PJ, Green CD, Maddox JF, Ganey PE, Roth RA. Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 314, 1023-1031, 2005.

54) Luster-Teasley SL, Ganey PE, DiOrio M, Ward III JS, Maleczka Jr RE, Trosko JE, Masten SJ. Effect of byproducts from the ozonation of pyrene: biphenyl-2,2',6,6'-tetracarbaldehyde and biphenyl-2,2',6,6'-tetracarboxylic acid on gap junction intercellular communication and neutrophil function. Environ Toxicol Chem 24, 733-740, 2005.

55) Luyendyk JP, Maddox JF, Green, CD, Ganey PE, Roth RA. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology 40,1342-1351, 2004.

56) Kinser S, Sneed RA, Roth RA, Ganey PE. Neutrophils contribute to endotoxin enhancement of allyl alcohol hepatotoxicity. J Toxicol Environ Health 67, 911-928, 2004.

57) Luyendyk JP, Mattes WB, Burgoon LD, Zacharewski TR, Maddox JF, Cosma GN, Ganey PE, Roth RA. Gene expression analysis points to hemostasis in livers of rats cotreated with lipopolysaccharide and ranitidine. Toxicol Sci 80, 203-213, 2004.

58) Harrigan GG, Laplante RH, Cosma GN, Cockerell G, Goodacre R, Maddox JF, Luyendyk JP, Ganey PE, Roth RA. Application of high-throughput Fourier-transform infrared spectroscopy in toxicology studies: contribution to a study on the development of an animal model for idiosyncratic toxicity. Toxicol Letters 146,197-205, 2004.

59) Maddox JF, Domzalski AC, Roth RA, Ganey PE. 15-Deoxy Prostaglandin $J_2$ enhances allyl alcohol-induced toxicity in rat hepatocytes. Toxicol Sci 77, 290-298, 2004.

60) Copple BL, Rondelli CM, Maddox JF, Hoglen NC, Ganey PE, Roth RA. Modes of cell death in rat liver after monocrotaline exposure. Toxicol Sci 77, 172-182, 2004.

61) Hanumegowda UM, Copple BL, Shibuya M, Malle E, Ganey PE, Roth RA. Basement membrane and matrix metalloproteinases in monocrotaline-induced liver injury. Toxicol Sci 76, 237-246, 2003.

62) Roth RA, Luyendyk JL, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy--is there a connection? J Pharmacol Exp Ther 307, 1-8, 2003.

63) Yee SB, Ganey PE, Roth RA. The role of Kupffer cells and TNF-alpha in monocrotaline and bacterial lipopolysaccharide-induced liver injury. Toxicol Sci 71, 124-132, 2003.

64) Copple BL, Ganey PE, Roth RA. Liver inflammation during monocrotaline hepatotoxicity. Toxicology 190, 155-169, 2003.

65) Yee SB, Hanumegowda UM, Hotchkiss JA, Ganey PE, Roth RA. Role of neutrophils in the synergistic liver injury from monocrotaline and bacterial lipopolysaccharide exposure. Toxicol Sci 72, 43-56, 2003.

66) Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 307, 9-16, 2003.

67) Yee SB, Harkema JR, Ganey PE, Roth RA. The coagulation system contributes to synergistic liver injury from exposure to monocrotaline and bacterial lipopolysaccharide. Toxicol Sci 74, 457-69, 2003.

68) Yee SG, Hanumegowda UM, Copple BL, Shibuya M, Ganey PE, Roth RA. Endothelial cell injury and coagulation system activation during synergistic hepatotoxicity from monocrotaline and bacterial lipopolysaccharide coexposure. Toxicol Sci 74, 203-214, 2003.

69) Luyendyk JP, Barton CC, Copple BL, Ganey PE, Roth RA. Augmentation of aflatoxin $B_1$ hepatotoxicity by endotoxin: involvement of endothelium and the coagulation system. Toxicol Sci 72, 171-181, 2003.

70) Copple BL, Hanumegowda U, Moulin FM, Ganey PE, Roth RA. Thrombin and protease-activated receptor-1 agonists promote lipopolysaccharide-induced hepatocellular injury in perfused livers. J Pharmacol Exper Ther 305, 417-425, 2003.

71) Maddox JF, Roth RA, Ganey PE. Allyl alcohol activation of protein kinase C δ leads to cytotoxicity of rat hepatocytes. Chem Res Toxicol 16, 609-615, 2003.

72) Kinser S, Copple BL, Roth RA, Ganey PE. Enhancement of allyl alcohol hepatotoxicity by endotoxin requires extrahepatic factors. Toxicol Sci 69, 470-481, 2002.

73) Yee SB, Copple BL, Ganey PE, Roth RA. The temporal relationship between bacterial lipopolysaccharide and monocrotaline exposures influences toxicity: Shift in response from hepatotoxicity to nitric oxide-dependent lethality. J Toxicol Environ Hlth, Part A 65, 961-976, 2002.

74) Luyendyk J, Shores K, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure

alters aflatoxin $B_1$ hepatotoxicity: Benchmark dose analysis for markers of liver injury. Toxicol Sci 68, 220-225, 2002.

75) Copple BC, Woolley B, Banes A, Ganey PE, Roth RA. Anticoagulants prevent monocrotaline-induced hepatic parenchymal cell injury but not endothelial cell injury in the rat. Toxicol Appl Pharmacol 180, 186-196, 2002.

76) Copple BL, Banes A, Ganey PE, Roth RA. Endothelial cell injury and fibrin deposition in rat liver after monocrotaline exposure. Toxicol Sci 65, 309-318, 2002.

77) Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 300, 460-467, 2002.

78) Olivero J, Bezdecny SA, Ganey PE. A molecular motif required for the activation of rat neutrophil phospholipase $A_2$ by organochlorine compounds. Chem Res Toxicol 15, 153-159, 2002.

79) Olivero J, Ganey PE. Participation of Ca2+/calmodulin during activation of rat neutrophils by polychlorinated biphenyls. Biochem Pharmacol 62, 1125-1132, 2001.

80) Moulin F, Copple BL, Ganey PE, Roth RA. Hepatic and extrahepatic factors critical for liver injury during lipopolysaccharide exposure. Am J Physiol Gastrointest Liver Physiol. 281(6), G1423-G1431, 2001.

81) Ganey PE, Barton Y-W, Kinser S, Sneed RA, Barton CC, Roth RA. Involvement of cyclooxygenase-2 in the potentiation of allyl alcohol-induced liver injury by bacterial lipopolysaccharide. Toxicol Appl Pharmacol 174, 113-121, 2001.

82) Barton CC, Barton EX, Ganey PE, Kunkel SL, Roth RA. Bacterial lipopolysaccharide enhances aflatoxin B1 hepatotoxicity in rats by a mechanism that depends on tumor necrosis factor alpha. Hepatology 33, 66-73, 2001.

83) Barton CC, Ganey PE, Roth RA. Lipopolysaccharide augments aflatoxin $B_1$-induced liver injury through neutrophil-dependent and -independent mechanisms. Toxicol Sci 58, 208-215, 2000.

84) Yee SB, Kinser S, Hill DA, Barton CC, Hotchkiss JA, Harkema JR, Ganey PE, Roth RA. Synergistic hepatotoxicity from coexposure to bacterial endotoxin and the pyrrolizidine alkaloid monocrotaline. Toxicol Appl Pharmacol 166, 173-185, 2000.

85) Barton CC, Hill DA, Yee SB, Barton EX, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure augments aflatoxin $B_1$-induced liver injury. Toxicol Sci 55, 444-452, 2000.

86) Sneed RA, Buchweitz JP, Jean PA, Ganey PE. Pentoxifylline attenuates bacterial lipopolysaccharide-induced enhancement of allyl alcohol hepatotoxicity. Toxicol Sci 56, 203-210, 2000.

87) Ganey PE, Quensen JF, Mousa MA, Boyd ST, Wagner MA, Fischer LJ. Biological activity associated with noncoplanar polychlorinated biphenyls after microbial dechlorination of Aroclor 1242 and Aroclor 1254. Environ Toxicol Chem 19, 1311-1316, 2000.

88) Olivero-Verbel J, Ganey PE. Role of protein phosphorylation in activation of phospholipase $A_2$ by the polychlorinated biphenyl mixture Aroclor 1242. Toxicol Appl Pharmacol 163, 9-16, 2000.

89) Tithof PK, Olivero J, Ruehle K, Ganey PE. Activation of neutrophil calcium-dependent and -independent phospholipases $A_2$ by organochlorine compounds. Toxicol Sci 53, 40-47, 2000.

90) Olivero-Verbel J, Ganey PE. Effect of three polychlorinated biphenyls on f-met-leu-phe-induced degranulation in rat neutrophils. Toxicol Lett 98, 195-202, 1998.

91) Brown AP, Olivero-Verbel J, Holdan WL, Ganey PE. Neutrophil activation by polychlorinated biphenyls: Structure -activity relationship. Toxicol Sci 46, 308-316, 1998.

92) Tithof PK, Peters-Golden M, Ganey PE. Distinct phospholipases $A_2$ regulate the release of arachidonic acid for eicosanoid production and superoxide anion generation in neutrophils. J Immunolog 160, 953-960, 1998.

93) Narayanan PK, Carter WO, Ganey PE, Roth RA, Voytik-Harbin SL, Robinson JP. Impairment of human neutrophil oxidative burst by polychlorinated biphenyls: Inhibition of superoxide dismutase activity. J Leuk Biol 63, 216-224, 1998.

94) Roth RA, Harkema JR, Pestka JP, Ganey PE. Is exposure to bacterial endotoxin a determinant of susceptibility from xenobiotic agents? Toxicol Appl Pharmacol 147, 300-311, 1997.

95) Molnar RG, Wang P, Ayala A, Ganey PE, Roth RA, Chaudry IH. The role of neutrophils in producing hepatocellular dysfunction during the hyperdynamic stage of sepsis in rats. J Surg Res 73, 117-122, 1997.

96) Tithof PK, Watts S, Ganey PE. Protein tyrosine kinase involvement in the production of superoxide anion by neutrophils exposed to Aroclor 1242, a mixture of polychlorinated biphenyls. Biochem Pharmacol 53, 1833-1842, 1997.

97) Sneed RA, Grimes SD, Schultze AE, Brown AP, Ganey PE. Bacterial endotoxin enhances the hepatotoxicity of allyl alcohol. Toxicol Appl Pharmacol 144, 77-87, 1997.

98) Srinavasan R, Buchweitz JP, Ganey PE. Alteration by flutamide of neutrophil response to stimulation: Implications for tissue injury. Biochem Pharmacol 53, 1179-1185, 1997.

99) Brown AP, Harkema JR, Schultze AE, Roth RA, Ganey PE. Gadolinium chloride pretreatment protects against hepatic injury but predisposes the lungs to alveolitis after lipopolysaccharide administration. Shock 7, 186-192,1997.

100) Moulin F, Pearson JM, Schultze AE, Scott MA, Schwartz KA, Davis JM, Ganey PE, Roth RA. Thrombin is a distal mediator of lipopolysaccharide-induced liver injury in the rat. J Surg Res 65, 149-158, 1996.

101) Jaeschke H, Smith CW, Clemens MG, Ganey PE, Roth RA. Mechanisms of inflammatory liver injury: Adhesion molecules and cytotoxicity of neutrophils. Toxicol Appl Pharmacol 139, 213-226, 1996.

102) Brown AP, Schultze AE, Holdan W, Buchweitz JP, Roth RA, Ganey PE. Lipopolysaccharide-induced hepatic injury is enhanced by polychlorinated biphenyls. Environ Hlth Perspec 104, 634-640, 1996.

103) Pearson JM, Brown AP, Ganey PE, Roth RA. Gadolinium chloride treatment attenuates hepatic platelet accumulation after lipopolysaccharide administration. Shock 5(6), 408-415, 1996.

104) Ho JS, Buchweitz JP, Roth RA, Ganey PE. Identification of factors from rat neutrophils responsible for cytotoxicity to isolated hepatocytes. J Leukocyte Biol 59, 716-724, 1996.

105) Wagner JG, Ganey PE, Roth RA. Nitric oxide is not involved in hepatocyte killing by

neutrophils activated *in vitro* by fmlp or PMA. Hepatology 23, 803-810, 1996.

106) Tithof PK, Schiamberg E, Peters-Golden M, Ganey PE. Phospholipase $A_2$ is involved in the mechanism of activation of neutrophils by polychlorinated biphenyls. Environ Hlth Perspect 104, 52-58, 1996.

107) Ganey PE, Schultze AE. Depletion of neutrophils and modulation of Kupffer cell function in allyl alcohol-induced hepatotoxicity. Toxicology 99, 99-106, 1995.

108) Brown AP, Ganey PE. Neutrophil degranulation and superoxide production induced by polychlorinated biphenyls are calcium-dependent. Toxicol Appl Pharmacol 131, 198-205, 1995.

109) Tithof PK, Contreras ML, Ganey PE. Aroclor 1242 stimulates the production of inositol phosphates in polymorphonuclear neutrophils. Toxicol Appl Pharmacol 131, 136-143, 1995.

110) Ganey PE, Bailie MB, VanCise S, Colligan ME, Madhukar BV, Robinson JP, Roth RA. Activated neutrophils from rat injured isolated hepatocytes. Lab Invest 70, 53-60, 1994.

111) Ganey PE, Sirois JE, Denison M, Robinson JP, Roth RA. Neutrophil function after exposure to polychlorinated biphenyls *in vitro*. Environ Hlth Perspect 101, 430-434, 1993.

112) Durak G, Lawler G, Kelley S, Ragheb K, Roth RA, Ganey P, Robinson JP. Time interval gating for analysis of cell function using flow cytometry. Cytometry 12, 701-706, 1991.

113) Ganey PE, Carter LS, Mueller RA, Thurman, RG. Doxorubicin toxicity in perfused rat heart: Effect of oxygen tension. Circ Res 68, 1610-1613, 1991.

114) Thurman RG, Ganey PE, Yi-ren W. Role of oxygen in regulation of metabolism of substituted organic amines in perfused mouse liver. Progr Pharmacol Clin Pharmacol 8(3), 177-183, 1991.

115) Ganey PE, Keller B, Lichtman SN, Lemasters JJ, Thurman RG. A new method to monitor Kupffer cell phagocytosis continuously in perfused rat liver. Hepatology 13, 567-574, 1991.

116) Ganey PE, Thurman RG. Ethanol potentiates doxorubicin-induced inhibition of cell

survival in cultured Chinese hamster ovary cells. Cancer Res 51, 2036-2040, 1991.

117) Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA. Development of morphologic, hemodynamic and biochemical changes in lungs of rats given monocrotaline pyrrole. Toxicol Appl Pharmacol 106, 179-200, 1990.

118) Wu Y, Kauffman FC, Qu W, Ganey PE, Thurman RG. Unique role of oxygen in regulation of hepatic monooxygenation and glucuronidation. Molec Pharmacol 38, 128-133, 1990.

119) Ganey PE, Takei Y, Kauffman FC, Thurman RG. Ethanol potentiates hepatotoxicity due to menadione in perfused rat liver. Molec Pharmacol 38, 959-964, 1990.

120) Badr MZ, Ganey PE, Yoshihara H, Kauffman FC, Thurman RG. Hepatotoxicity of menadione predominates in oxygen-rich zones of the liver lobule. J Pharmacol Exp Ther 248, 1317-1322, 1989.

121) Ganey PE, Sprugel KH, White SM, Wagner JG, Roth RA. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia. Am J Physiol 255, H1165-H1172, 1988.

122) Ganey PE, Kauffman FC, Thurman RG. Oxygen-dependent hepatotoxicity due to doxorubicin: Role of reducing equivalent supply in perfused rat liver. Mol Pharmacol 34, 695-701, 1988.

123) Ganey PE, Roth RA. 6-Ketoprostaglandin $F_{1\alpha}$ and thromboxane $B_2$ in isolated, blood-perfused lungs from monocrotaline pyrrole-treated rats. J Toxicol Environ Hlth 23, 127-137, 1988.

124) Ganey PE, Roth RA. Elevated serum copper concentration in monocrotaline pyrrole-treated rats with pulmonary hypertension. Biochem Pharmacol 36, 3535-3537, 1987.

125) Ganey PE, Roth RA. 5-Hydroxytryptamine and thromboxane in platelets from rats treated with monocrotaline pyrrole. Toxicol Appl Pharmacol 88, 157-164, 1987.

126) Ganey PE, Roth RA. 6-Ketoprostaglandin $F_{1\alpha}$ and thromboxane $B_2$ in isolated, buffer-perfused lungs from monocrotaline pyrrole-treated rats. Exper Lung Res 12, 195-206, 1987.

127) Ganey PE, Roth RA. Thromboxane does not mediate the pulmonary vascular response

to monocrotaline pyrrole. Am J Physiol 252, H743-H748, 1986.

128) Ganey PE, Sprugel KH, Hadley KB, Roth RA. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin. J Pharmacol Exp Ther 237, 226-231, 1986.

129) Ganey PE, Fink GD, Roth RA. The effect of dietary restriction and altered sodium intake on the cardiopulmonary toxicity of monocrotaline pyrrole. Toxicol Appl Pharmacol 78, 55-62, 1985.

**Book Chapters:**

1) Ganey PE, Misek SA. Signal transduction in disease: Relating cell signaling to morbidity and mortality. Chapter 4 in: Cellular Signal Transduction in Toxicology and Pharmacology, Data Collection, Analysis, and Interpretation: (JW Boyd and RR Neubig, eds) Wiley Press, Hoboken, NJ, 2019, pp XX-XXX. ISBN-13: 978-1119060260

2) Roth RA, Ganey PE. Role of inflammation in drug-induced liver injury. Chapter 10 in: Drug-Induced Liver Disease: (N Kaplowitz and LD DeLeve, eds), Academic Press, Elsevier, London, UK, 2013, pp. 157-174. ISBN: 978-0-12-387817-5

3) Dugan CM, Ganey PE, Roth RA. Animal models of idiosyncratic, drug-induced liver injury. Chapter 25 in: New Horizons in Predictive Toxicology (AGE Wilson, ed), Royal Society of Chemistry, Thomas Graham House, Cambridge, UK, 2012, pp. 642-664.

4) Luyendyk JP, Roth RA, Ganey PE. Inflammation and hepatotoxicity. Chapter 13 In: Comprehensive Toxicology, Volume 9: Hepatic Toxicology (CA McQueen, ed), Academic Press, Elsevier, London, UK 2010, pp. 295-317.

5) Roth RA, Ganey PE. Inflammation and drug-induced liver injury. Chapter 47 In: The Liver: Biology and Pathobiology (IM Arias, HJ Alter, JL Boyer, DE Cohen, N Fausto, DA Shafritz and AW Wolkoff, eds.). Wiley-Blackwell Publishers: West Sussex, UK, 2009, pp.773-781.

6) Roth RA, Ganey PE. Biomarkers of organ injury from chemical exposure: Concurrent inflammation as a determinant of suseptibility. Chapter 29 In: Biomarkers of Environmentally Associated Disease: Technologies, Concepts, and Perspectives (SH Wilson and WA Suk, eds.). Lewis Pubs: Boca Raton, FL, 2002, pp. 431-444.

7) Ganey PE, Roth RA, Dahm LJ. Allyl alcohol. In: Comprehensive Toxicology, Volume 9: Hepatic and Gastrointestinal Toxicology (IG Sipes, CA McQueen and AJ Gandolfi, eds.), Elsevier Publishing, 1997, pp. 455-463.

8) Dahm LJ, Ganey PE, Roth RA. α-Naphthylisothiocyanate. In: Comprehensive Toxicology, Volume 9: Hepatic and Gastrointestinal Toxicology (IG Sipes, CA McQueen and AJ Gandolfi, eds.), Elsevier Publishing, 1997, pp. 447-454.

9) Ganey PE. Amyl acetate. In: Ethel Browning's Toxicity and Metabolism of Industrial Solvents, Alcohols and Esters, 2nd edition, Vol. 3 (RG Thurman and FC Kauffman,

eds.), Elsevier Science Publishers B.V., 1992, pp. 262-267.

10) Ganey PE. Hexanols. In: Ethel Browning's Toxicity and Metabolism of Industrial Solvents, Alcohols and Esters, 2nd edition, Vol. 3 (RG Thurman and FC Kauffman, eds.), Elsevier Science Publishers B.V., 1992, pp. 176-183.

11) Thurman RG, Ganey PE, Belinsky SA, Conway JG, Badr MZ, Kauffman FC. Advantages of the perfused liver as a model to study hepatotoxicity in periportal and pericentral regions of the liver lobule. In: *In Vitro* Toxicology: Model Systems and Methods (CA McQueen, ed.), Telford Press, 1989, pp. 69-91.

**Reviews:**

1) Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M. Current challenges and controversies in drug-induced liver injury. Drug Safety 35(12): 1099-1117, 2012. PMID: 23137150

2) Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury-Current status. Crit Rev Toxicol. Oct;41(9):723-39, 2011.

3) Deng X, Luyendyk JP, Ganey PE, Roth RA. Inflammatory stress and idiosyncratic hepatotoxicity: Hints from animal models. Pharmacol Rev 61, 262-282, 2009.

4) Ganey PE, Boyd SA. An approach to evaluation of the effect of bioremediation on biological activity of environmental contaminants: Dechlorination of polychlorinated biphenyls. Environ Health Persp 113, 180-185, 2005.

5) Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 150, 35-51, 2004.

6) Ganey PE, Roth RA. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicology 169(3), 195-208, 2001.

7) Mousa MA, Ganey PE, Quensen JF, Madhukar BV, Chou K, Giesy JP, Fischer LJ, Boyd SA. Altered biological activities of commercial PCB mixtures after microbial reductive dechlorination. Environ Health Persp 106, 1409-1418, 1998.

8) Fischer LJ, Seegal RF, Ganey PE, Pessah IN, Kodavanti PRS. Toxicity of non-coplanar

PCBs. Toxicol Sci 41, 49-61, 1998.

9) Roth RA, Ganey PE. Platelets and the puzzles of pulmonary pyrrolizidine poisoning. Fund Appl Toxicol 93, 463-471, 1988.

10) Roth RA, Ganey PE. Arachidonic acid metabolites and the mechanisms of monocrotaline pneumotoxicity. Am Rev Resp Dis 136, 762-765, 1987

**Commentary:**

Roth RA, Ganey PE. Successes and frustrations in developing animal models of idiosyncratic drug reactions. Chem Biol Interact 152, 165, 2005.

**Abstracts:**

1) Mollon H, Roth R, Ganey P. Use of cytotoxic TNF interaction to classify drugs according to their ability to cause idiosyncratic, drug-induced liver injury: Influence of classification modeling and of categorization criteria. The Toxicologist 168(1): 265, 2019.

2) Murphy RA, Mollon HN, Turkus J, Roth R, Ganey P. Cytotoxic interaction with tumor necrosis factor-alpha in HepG2 cells cccurs with drugs that cause a hepatocellular rather than a cholestatic pattern of idiosyncratic hepatotoxicity. The Toxicologist 162(1): 75, 2018.

3) Rice GP, Hibbard N, Murphy RA, Roth RA, Ganey PE, McKim JM. Flutamide interaction with bile acid and tumor necrosis factor-alpha in human hepatocytes: implication for the pathogenesis of cholestatic, drug-induced liver injury. The Toxicologist 162(1): 78, 2018.

4) Hession SL, Maiuri AR, Ganey PE, Roth RA. Using points of departure from partial concentration-response relationships for cytotoxic TNF-drug interaction to classify drugs according to their potential to cause idiosyncratic, drug-induced liver injury. The Toxicologist 162(1): 77, 2018.

5) Mollon H, Maiuri AR, Murphy RA, Turkus JD, Rice GP, McKim JM, Ganey PE, Roth RA. Use of cytotoxic TNF interaction to classify drugs according to their ability to cause idiosyncratic, drug-induced liver injury: assay reproducibility and high-throughput application. The Toxicologist 162(1): 87, 2018.

6) Ramirez FE, Nedley N, Seo S, Ganey PE. An 8-week educational program improves mental health of individuals exposed to toxins. The Toxicologist 156(1): 176, 2017.

7) Maiuri A, Wassink B, Turkus J, Breier A, Lansdell T, Kaur G, Ganey P, Roth R. A. promising, in vitro approach to classify drugs according to their potential to cause idiosyncratic, drug-induced liver injury. The Toxicologist 150(1): 237, 2016.

8) Roth RA, Maiuri AR, Ganey PE. Drugs associated with idiosyncratic liver injury synergize with TNF and IFNg to cause death of hepatocytes: Role of MAPK activation. The Toxicologist 150(1): 355, 2016.

9) Maiuri A, Gora L, Breier AB, Turkus J, Ganey PE, Roth RA. Cytotoxic synergy between cytokines and NSAIDs associated with idiosyncratic hepatotoxicity is driven by mitogen-activated protein kinases. The Toxicologist 144(1): 21, 2015.

10) Breier AB, Maiuri A, Roth RA, Ganey PE. Calpain inhibition protects HepG2 cells from cytotoxicity induced by treatment with NSAIDs in combination with inflammatory cytokines: Implications for idiosyncratic hepatotoxicity. The Toxicologist 144(1): 289, 2015.

11) Miyakawa K, Albee R, Letzig LG, Lehner AF, Scott M, Buchweitz JP, James LP, Ganey PE, Roth RA. A cytochrome P450-independent mechanism of acetaminophen-induced hepatocellular injury. FASEB, 416.4, 2015.

12) Maiuri A, Breier A, Turkus J, Lansdell T, Kaur G, Parkins R, Ganey P, Roth R. Drugs associated with idiosyncratic hepatotoxicity synergize with cytokines to kill hepatocytes in vitro. FASEB, 937.7, 2015.

13) Miyakawa K, Sullivan BP, Albee RP, Singhal R, Scott MA, Luyendyk JP, Ganey PE, Roth RA. Contribution of PAR-4 and thrombin to acetaminophen hepatotoxicity in mice. The Toxicologist 138:315, 2014.

14) Maiuri A, Gora L, Parkins R, Ganey PE, Roth R. NSAIDs synergize with inflammatory cytokines to kill hepatocytes: Implications in idiosyncratic reactions. The Toxicologist 138:316, 2014.

15) Poulsen KL, Albee RP, Ganey PE, Roth RA. Trovafloxacin potentiates lipopolysaccharide-induced tumor necrosis factor release in RAW cells in an ERK-dependent manner. The Toxicologist 138:494, 2014.

16) Beggs KM, Ganey PE, Roth RA. Trovafloxacin-induced DNA damage in HepG2 cells causes p21 upregulation and activation of ATR and sensitizes cells to TNR-mediated cytotoxicity involving ERK. The Toxicologist 138:495, 2014.

17) Miyakawa K, Albee R, Scott M, Ganey PE, Luyendyk J, Roth RA. Platelet depletion reduces acetaminophen hepatotoxicity in mice. The Toxicologist 132:135, 2013.

18) Poulsen KL, Ganey PE, Roth RA. Trovafloxacin-induced TNF expression in Raw cells is ATR-dependent. The Toxicologist 132:141, 2013.

19) Maiuri A, Parkins R, Ganey PE, Roth RA. Drugs associated with idiosyncratic drug-induced liver injury synergize with inflammatory mediators to produce cytotoxicity in a human hepatoma cell line. The Toxicologist 132:226, 2013.

20) Roth RA, Wilga PC, Poulsen KL, Beggs KM, Prezenger J, Maiuri A, Ganey PE, McKim J. Cytotoxic interaction of inflammagens with trovafloxacin in spheroid cultures of rat liver cells. The Toxicologist 132:230, 2013.

21) Beggs KM, Miyakawa K, Scott MA, Ganey PE, Roth RA. Trovafloxacin induces cell cycle arrest and sensitizes HepG2 cells to TNF-induced cytotoxicity by an ATR-dependent mechanism. The Toxicologist 132:230, 2013.

22) Lu J, Roth RA, Ganey PE. Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in hepa1c1c7 cells: Roles of caspase activation and oxidative stress. Abstract 704, The Toxicologist 126: 152-153, 2012.

23) Singhal R, Ganey PE, Roth RA. The role of complement activation in acetaminophen-induced liver injury in mice. Abstract 352, The Toxicologist 126: 75, 2012.

24) Fullerton AM, Roth RA, Ganey PE. TCDD exacerbates concanavalin A-induced liver injury and reveals a critical role for NK cells in a model of immune-mediated liver injury. Abstract 699, The Toxicologist 126:151-152, 2012.

25) Lu J, Roth RA, Ganey PE. The hemostatic system and neutrophils in amiodarone/lipopolysaccharide-induced liver injury in rats. Abstract 433, The Toxicologist, Toxicol Sci 120, Supplement 2: 93, 2011.

26) Singhal R, Poulsen KL, Ganey PE, Roth RA. Trovafloxacin enhancement of LPS-mediated signaling is associated with reduced SOCS-1 expression. Abstract 443, The Toxicologist, Toxicol Sci 120, Supplement 2: 95, 2011.

27) Poulsen KL, Beggs K, Singhal R, Ganey PE, Roth RA. Trovafloxacin promotes DNA double-strand breaks in a macrophage cell line. Abstract 878, The Toxicologist, Toxicol Sci 120, Supplement 2: 188, 2011.

28) Fullerton AM, Roth RA, Ganey PE. TCDD enhances the response of innate immune cells to concanavalin A administration. Abstract 1093, The Toxicologist, Toxicol Sci 120, Supplement 2: 233-234, 2011.

29) Sparkenbaugh EM, Nothem MA, Ganey PE, Roth RA. The cytotoxic interaction between hypoxia and neutrophil elastase in a murine hepatoma cell line is independent of HIF-1α signaling. Abstract 1652, The Toxicologist, Toxicol Sci 120, Supplement 2: 355-356, 2011.

30) Beggs KM, Ganey PE, Roth RA. Apoptosis and cell proliferation in HepG2 cells treated with trovafloxacin and tumor necrosis factor. Abstract 1658, The Toxicologist, Toxicol Sci 120, Supplement 2: 357, 2011.

31) Dugan CM, Roth RA, Ganey PE. A mouse model of severe halothane hepatitis based on human risk factors. Abstract 590, The Toxicologist, Toxicol Sci 114:126, 2010.

32) Lu J, Roth RA, Ganey PE. Characterization of an inflammatory stress model of amiodarone idiosyncratic hepatotoxicity in rats. Abstract 750, The Toxicologist, Toxicol Sci 114:159-160, 2010.

33) Fullerton AM, Roth RA, Ganey PE. TCDD enhances inflammatory liver injury in response to concanavalin A administration. Abstract 1952, The Toxicologist, Toxicol Sci 114:415, 2010.

34) Zou W, Roth RA, Younis HS, Burgoon LD, Ganey PE. Oxidative stress is a potential player in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide. Abstract 1956, The Toxicologist, Toxicol Sci 114:416, 2010.

35) Beggs KM, Ganey PE, Roth RA. Trovafloxacin and tumor necrosis factor-α interact to cause cell death in HepG2 cells. Abstract 2123, The Toxicologist, Toxicol Sci 114:451, 2010.

36) Poulsen KL, Singhal R, Ganey PE, Roth RA. Trovafloxacin potentiates LPS-induced TNFα expression in a macrophage cell line. Abstract 2125, The Toxicologist, Toxicol Sci 114:452, 2010.

37) Singhal R, Maddox JF, Lehman-McKeeman LD, Reilly TP, Tirmenstein MA, Bhaskaran VM, Ganey PE, Roth RA. The role of Toll-like receptor 4 in acetaminophen hepatotoxicity. Abstract 2136, The Toxicologist, Toxicol Sci 114:454, 2010.

38) Sparkenbaugh EM, Saini Y, LaPres JJ, Maddox JF, Ganey PE, Roth RA. HIF-1α deletion protects mice from acetaminophen hepatotoxicity and reduces activation of the hemostatic system. Abstract 2137, The Toxicologist, Toxicol Sci 114:454, 2010.

39) Traore K, Singhal R, Rivera R, Ganey PE, Rothr R. Aflatoxin B1 inhibits LPS-induced TNF-alpha production in RAW 264.7 cells. Abstract 4378,Cancer Res (8 Suppl) 70, 2010.

40) Ibrahim Aibo D, Maddox J, Birmingham N, Ganey P, Roth R, Wagner J, Harkema J. Rle of interleukin-6 in ozone exacerbation of acetaminophen-induced liver injury. Abstract 2139, The Toxicologist, Toxicol Sci 114:455, 2010.

41) Zou W, Beggs KM, Sparkenbaugh EM, Jones AD, Roth RA, Ganey PE. Sulindac metabolite and TNFa interaction in liver injury induced by sulindac and lipopolysaccharide in rats. *FASEB J* 23:741.5, 2009.

42) Sparkenbaugh E, Traore K, Greenwood K, Ganey P, Roth R. Hypoxia and neutrophils elastase interact to cause hepatocellular injury and increase oxidative stress and phosphorylation of p38 MAPK, Abstract 70, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2009.

43) Deng X, Sparkenbaugh E, Liguori M, Waring J, Blomme E, Ganey P, Roth R. Gene expression profiles in livers from diclofenac-treated rats reveal intestinal bacteria-dependent and –independent pathways associated with liver injury. Abstract 1133, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2009.

44) Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, Ganey PE. Hepatotoxic interaction of sulindac with lipopolysaccharide: Role of the hemostatic system. Abstract 1134, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2009.

45) MacDonald AE, Dugan CM, Roth RA, Ganey PE. Ovarian hormones sensitize the liver to halothane-induced hepatotoxicity in female mice. Abstract 1143, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2009.

46) Shaw PF, Beggs KM, Ganey PE, Roth RA. Trovafloxacin and tumor necrosis factor $\alpha$ synergize to cause liver injury in a murine model of idiosyncratic toxicity. Abstract

1152, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2009.

47) Dugan CM, MacDonald AE, Roth RA, Ganey PE. Gender-dimorphic inflammatory response in halothane hepatitis in mice. Abstract 1883, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2009.

48) Ibrahim Aibo D, Stokes J, Birmingham N, Maddox J, Roth R, Harkema JR, and Ganey P. Ozone-induced exacerbation of acute liver injury in mice. Abstract 2083, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2009.

49) Lu J, Roth RA, Ganey PE. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats. Abstract 2170, The Toxicologist CD — An official Journal of the Society of Toxicology, Volume 102, Number S-1, March 2009.

50) Shaw PJ, Ditewig AC, Waring JF, Ligouri MJ, Blomme EA, Copple BL, Ganey PE, Roth RA. Coexposure of mice to trovafloxacin and lipopolysaccharide results in a unique gene expression profile and liver injury dependent on early growth response-1 transcription factor activation. The FASEB Journal 22, Abstract 709.8, 2008.

51) Deng X, Lu J, Lehman-McKeeman L, Malle E, Crandall D, Ganey P, Roth R. Role of TNF converting enzyme in TNF production, neutrophil activation and liver injury in hepatotoxic interaction of lipopolysaccharide and ranitidine. The FASEB Journal 22, Abstract 709.7, 2008.

52) Ganey PE, Olivero JT, Roth RA. Dioxin alters inflammatory responses to lipopolysaccharide. The Toxicologist, Toxicol Sci 102, 174 (Abstract # 853), 2008.

53) Olivero JT, Gaynor H, Roth R, Ganey P E. The contribution of PPAR-alpha to hepatic responses in a mouse model of inflammation-dioxin interaction. The Toxicologist, Toxicol Sci 102, 175 (Abstract # 854), 2008.

54) Zou W, Devi SS, Younis HS, Roth RA, Ganey PE. Inflammation-mediated liver injury in rats cotreated with sulindac and lipopolysaccharide. The Toxicologist, Toxicol Sci 102, 44 (Abstract # 220), 2008.

55) Shaw PJ, Ganey PE, Roth RA. Trovafloxacin enhances the inflammatory response to a gram-negative or a gram-positive stimulus, resulting in neutrophil-dependent liver injury in mice. The Toxicologist, Toxicol Sci 102, 127 (Abstract #623), 2008.

56) Deng X, Lu J, Lehman-McKeeman L, Malle E, Ganey P, Roth R. Role of P38 MAPK kinase in TNF-a production and liver injury in hepatotoxic interaction of lipopolysaccharide and ranitidine. The Toxicologist, Toxicol Sci 102, 174 (Abstract #849), 2008.

57) Dugan CM, Roth RA, Ganey PE. Determinants of sensitivity to halothane-induced hepatotoxicity in mice. The Toxicologist, Toxicol Sci 102, 174 (Abstract #850), 2008.

58) Luyendyk JP, Ganey PE, Newport SW, Eagle TM, Maddox JF, Mackman N, Roth RA. Role of tissue factor and protease activated receptor-1 in acetaminophen-induced hepatotoxicity in mice. The Toxicologist, Toxicol Sci 102, 171 (Abstract # 837), 2008.

59) Roth RA, Shaw PF, Ditewig AC, Waring JF, Liguori MF, Blomme EA, Briscoe DM, Ganey PE. Coexposure of mice to trovafloxacin and lipopolysaccharide results in a unique gene expression profile and vascular endothelial growth factor (VEGF)-dependent liver injury. The Toxicologist, Toxicol Sci 102, 173 (Abstract # 847), 2008.

60) Sparkenbaugh E, Shaw P, Ganey PE, Roth RA, Ditewig A, Blomme EA, Liguori M, Waring JF. Microarray analysis of trovafloxacin-induced gene expression changes in human hepatocytes compared to hepatocytes isolated from rats treated with LPS. The Toxicologist, Toxicol Sci 102, 248-249 (Abstract # 1208), 2008.

61) Fullerton AM, Shaw PJ, Ganey PE, Roth RA. Hemostatic system activation contributes to hepatotoxicity in mice treated with trovafloxacin and lipopolysaccharide. The Toxicologist, Toxicol Sci 102, 173 (Abstract #848), 2008.

62) Birmingham N, Ibrahim Aibo D, Maddox JF, Newport SW, Roth RA, Ganey PE, Harkema JR. Endotoxin enhances acetaminophen-induced nasal toxicity in mice. The Toxicologist, Toxicol Sci 102, 393 (Abstract # 1912), 2008.

63) Ibrahim Aibo D, Birmingham N, Maddox JF, Newport SW, Roth RA, Ganey PE, Wagner JG, Harkema JR. Synergistic toxic effects of acetaminophen and ozone on murine nasal epithelium. The Toxicologist, Toxicol Sci 102, 393-394 (Abstract # 1913), 2008.

64) Shaw PJ, Fullerton AM, Ganey PE,Roth RA. Co-exposure to trovafloxacin and lipopolysaccharide causes tumor necrosis factor alpha-dependent liver injury: a murine model of idiosyncratic liver injury. FASEB J 21(6), A#867.14, 2007.

65) Shaw PJ, Ganey PE, Roth RA. Co-exposure of mice to trovafloxacin and lipopolysaccharide leads to an altered inflammatory response in a mouse model of idiosyncratic liver injury. The Toxicologist, Toxicol Sci 96, 129 (Abstract #624), 2007.

66) Zou W, Devi SS, Lecureux L, Lehman-McKeeman L, Nelson D, Roth RA, Ganey PE. Hepatocellular injury and gene expression analysis in livers of rats co-treated with lipopolysaccharide and chlorpromazine. The Toxicologist, Toxicol Sci 96, 150-151 (Abstract #732), 2007.

67) Devi SS, Luyendyk JP, Liguori MJ, Blomme EA, Waring JE, Ganey PE, Roth RA. Gene expression analysis of livers from rats co-treated with lipopolysaccharide and aflatoxin B1. The Toxicologist, Toxicol Sci 96, 151 (Abstract #733), 2007.

68) Deng X, Luyendyk J, Zou W, Tukov F, Lu J, Malle E, Ganey P, Roth R. Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. The Toxicologist, Toxicol Sci 96, 179 (Abstract #868), 2007.

69) Liguori MJ, Deng X, Blomme E, Stachlewitz R, Waring J, Maddox J, Ganey P, Roth R. Enhanced hepatic gene expression of stress-response factors in rats with diclofenac-induced hepatotoxicity: Role of GI bacterial endotoxin. The Toxicologist, Toxicol Sci 96, 286 (Abstract #1381), 2007.

70) Bezdecny SA, Roth RA, Ganey PE. Regulation of cyclooxygenase-2 in granulocytic HL-60 cells by 2,2',4,4'-tetrachlorobiphenyl involves transcriptional changes and changes in mRNA stability. The Toxicologist, Toxicol Sci 90, 20 (Abstract # 97), 2006.

71) Amuzie CJ, Li M, Ganey PE, Roth RA, Cuff CF, Pestka JJ. Reovirus exposure potentiates acetaminophen hepatotoxicity. The Toxicologist, Toxicol Sci 90, 204 (Abstract # 999), 2006.

72) Deng X, Stachlewitz RF, Liguori MJ, Blomme EAG, Waring JF, Luyendyk JP, Maddox JF, Ganey PE, Roth RA. Modest inflammation enhances diclofenac hepatotoxicity in rats: a potential animal model for idiosyncratic drug reaction. The Toxicologist, Toxicol Sci 90, 350-351 (Abstract # 1711), 2006.

73) Newport SW, Eagle TM, Ganey PE, Roth RA, Maddox JF. Hepatic fibrin deposition during the development of lipopolysaccharide-potentiated acetaminophen toxicity. The Toxicologist, Toxicol Sci 90, 205 (Abstract # 1005), 2006.

74) Eagle TM, Newport SW, Maddox JF, Luyendyk JP, Ganey PE, Roth RA. Heparin attenuates acetaminophen-induced hepatotoxicity in mice. The Toxicologist, Toxicol Sci 90, 204 (Abstract # 1002), 2006.

75) Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, North C, Blomme EA, Roth RA. LPS-cotreated rats as a model for trovafloxacin-induced idiosyncratic hepatotoxicity. The Toxicologist, Toxicol Sci 90, 350 (Abstract # 1708), 2006.

76) Shaw PJ, Luyendyk JP, Ganey PE, Roth RA. Hypoxia potentiates hepatocellular killing by neutrophil mediators in vitro. The Toxicologist, Toxicol Sci 90, 440 (Abstract # 2148), 2006.

77) Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Reilly TP, Car BD, Cantor GH, Maddox JF, Ganey PE, Roth RA. Coagulation-dependent gene expression and injury in livers of rats given lipopolysaccharide with ranitidine but not with famotidine. The Toxicologist, Toxicol Sci 90, 350 (Abstract # 1710), 2006.

78) Tukov FF, Maddox JF, Amacher DE, Roth RA, Ganey PE. Kupffer cell/hepatocyte coculture as a model to assess xenobiotic-inflammation interactions. The Toxicologist, Toxicol Sci 90, 352 (Abstract # 1718), 2006.

79) Liguori MJ, Waring JF, Luyendyk JP, Deng X, Maddox JF, Ganey PE, Stachlewitz RF, Blomme EA, Mattes WB, Cosma GN, Roth RA. Three distinct pharmacologic agents associated with human idiosyncratic hepatotoxicity display commonalities in gene expression profiles in LPS co-treated rats. The Toxicologist, Toxicol Sci 90, 389-390 (Abstract # 1905), 2006.

80) Ganey PE. The contribution of Kupffer cell-derived mediators to acute hepatotoxicity. The Toxicologist, Toxicol Sci 90, 229 (Abstract # 1123), 2006.

81) Bezdecny S, Roth R, Ganey P. The role of superoxide anion in 2,2',4,4'-tetrachlorobiphenyl-induced upregulation of COX-2 in HL-60 cells. The Toxicologist, Toxicol Sci 84,420 (Abs # 2052), 2005.

82) Luyendyk JP, Green CD, Maddox JF, Ganey PE, Roth RA. Inhibition of coagulation system activation attenuates liver hypoxia in rats cotreated with lipopolysaccharide and ranitidine. FASEB J 19(4 Pt 1), (A. #86.2), 2005.

83) Luyendyk J, Lehman-McKeeman L, Nelson D, Bhaskaran V, Car B, Cantor G, North C, Newport S, Maddox J, Ganey P, Roth R. Augmentation of lipopolysaccharide-

induced gene expression and liver injury by ranitidine but not famotidine. The Toxicologist, Toxicol Sci 84, 394-395 (Abs # 1930), 2005.

84) Newport S, Dugan C, Deng X, Ganey P, Roth R, Maddox J. Lipopolysaccharide potentiates acetaminohen hepatotoxicity. The Toxicologist, Toxicol Sci 84, 14-15 (Abs # 69), 2005.

85) Bezdecny S, Roth RA, Ganey PE. 2,2',4,4'-Tetrachlorobiphenyl stimulates release of arachidonic acid from neutrophilic HL-60 cells. The Toxicologist, Toxicol Sci 78 S-1, 292, 2004.

86) Luyendyk JP, Mattes WB, Maddox JF, Cosma GN, Ganey PE, Roth RA. Altered gene expression as a contributing factor to liver injury in rats cotreated with ranitidine and lipopolysaccharide. The Toxicologist, Toxicol Sci 78 S-1, 101-102, 2004.

87) Roth RA, Copple BL, Rondelli CM, Maddox JF, Hoglen NS, Ganey PE. Modes of cell death in rat liver after monocrotaline exposure. The Toxicologist, Toxicol Sci 78 S-1, 101, 2004.

88) Copple BL, Ganey PE, Roth RA. Hypoxia in rat liver after monocrotaline exposure. The Toxicologist, Toxicol Sci 78 S-1, 101, 2004.

89) Maddox JF, Luyendyk JP, Cosma GN, Breau AP, Harrigan GG, Bible RH, Goodacre R, Ganey PE, Cantor GH, Cockerell GL, Roth RA. Metabonomic evaluation of idiosyncrasy-like liver injury in rats cotreated with ranitidine and lipopolysaccharide. The Toxicologist, Toxicol Sci78 S-1, 12, 2004.

90) Luyendyk JP, Maddox JF, Ganey PE, Roth RA. Coagulation system activation and fibrin deposition are critical factors in idiosyncrasy-like liver injury from lipopolysaccharide and ranitidine coexposure. FASEB J **18**, Abstract #645.5, 2004.

91) Bezdecny SA, Roth RA, Ganey PE. Expression of cyclooxygenase-2 in HL-60 cells exposed to polychlorinated biphenyls. Toxicol Sci 72, 324, 2003.

92) Maddox J, Roth RA, Ganey PE. 15-Deoxy-prostaglandin J2 enhances allyl alcohol-induced toxicity in rat hepatocytes. Toxicol Sci 72, 201, 2003.

93) Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Modest inflammation renders ranitidine hepatotoxic: Is there a relationship to drug idiosyncrasy? Toxicol Sci 72, 202, 2003.

94) Yee SB, Ganey PE, Roth RA. The role of the coagulation system in synergistic liver injury caused by monocrotaline and bacterial endotoxin coexposure. Toxicol Sci 72, 202, 2003.

95) Hanumegowda UM, Copple BL, Shibuya M, Ganey PE, Roth RA. Matrix metalloproteinases in monocrotaline-induced liver injury. Toxicol Sci 72, 202, 2003.

96) Copple BL, Woolley B, Rondelli C, Ganey PE, Roth RA. Activation of signal transduction pathways in hepatic parenchymal cells are required for neutrophil-dependent killing. Toxicol Sci 72, 200-201, 2003.

97) Yee SB, Copple BL, Ganey PE, Roth RA. Sinusoidal endothelial cell injury during hepatotoxicity from monocrotaline and bacterial lipopolysaccharide coexposure. Toxicol Sci 66, 352, 2002.

98) Luyendyk JP, Shores KC, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure alters aflatoxin B1 hepatotoxicity: Benchmark dose analysis for markers of liver injury. Toxicol Sci 66, 364, 2002.

99) Copple BL, Ganey PE, Roth RA. Endothelial cell injury and fibrin deposition in rat liver after monocrotaline exposure. Toxicol Sci 66, 366, 2002.

100) Kinser S, Roth RA, Ganey PE. Potentiation of allyl alcohol hepatotoxicity by endotoxin requires activation of the coagulation system. Toxicol Sci 66, 366-367, 2002.

101) Maddox JF, Tesheva N, Roth RA, Ganey PE. Activation of protein kinase C delta in allyl alcohol-induced toxicity in rat hepatocytes.. Toxicol Sci 66, 367, 2002.

102) Ganey PE, Barton YW, Kinser S, Sneed RA, Barton CC, Roth RA. Involvement of cyclooxygenase-2 in the potentiation of allyl alcohol-induced liver injury by bacterial lipopolysaccharide. Toxicol Sci 60, 177, 2001.

103) Yee SB, Ganey PE, Roth RA. Inflammatory events in the synergistic hepatotoxicity of monocrotaline and bacterial lipopolysaccharide. Toxicol Sci 60, 177, 2001.

104) Olivero-Verbel J, Ganey P, Fischer L, Wagner M. Moment of inertia: A molecular descriptor useful to determine the human half-lives of polychlorinated biphenyls and their capacity to induce insulin release from RinM5F cells. Toxicol Sci 60, 234, 2001.

105) Kinser S, Roth RA, Ganey PE. Hepatocellular GSH depletion by allyl alcohol and sensitivity to neutrophil-derived reactive oxygen species. Toxicol Sci 60, 350-351, 2001.

106) Copple BL, Perez Rivera AA, Ganey PE, Roth RA. Neutrophils and monocrotaline-induced liver injury. Toxicol Sci 60, 351, 2001.

107) Copple BL, Banes A, Ganey PE, Roth RA. Inflammation and apoptosis in rat liver induced by monocrotaline. Toxicol Sci 54, 41, 2000.

108) Ganey PE, Olivero-Verbel J, Madhukar BV. Mechanism of inhibition of stimulated neutrophil degranulation by 2,2',4,4'-tetrachlorobiphenyl. Toxicol Sci 54, 77, 2000.

109) Olivero-Verbel J, Ganey PE. A common electrotopological motif among organochlorine compounds that activate neutrophils. Toxicol Sci 54, 77, 2000.

110) Kinser S, Sneed RA, Roth RA, Ganey PE. Heparin or neutrophil depletion attenuates endotoxin-induced potentiation of allyl alcohol hepatotoxicity. Toxicol Sci 54, 139, 2000.

111) Barton CC, Barton EX, Ganey PE, Roth RA. Endotoxin porentiates aflatoxin $B_1$-induced hepatotoxicity through a TNF-α-dependent mechanism. Toxicol Sci 54, 140, 2000.

112) Yee SB, Ganey PE, Roth RA. Hepatotoxicity from coadministration of small, synergistic doses of monocrotaline and bacterial endotoxin is attenuated by heparin. Toxicol Sci 54, 140, 2000.

113) Buchweitz JP, Bursian S, Ganey PE, Roth RA. An animal model for idiosyncratic reactions to chlorpromazine. Toxicol Sci 54, 397-398, 2000.

114) Kinser S, Roth RA, Ganey PE. Potentiation of allyl alcohol hepatotoxicity by endotoxin requires extrahepatic factors. FASEB J 13(5), A738, 1999.

115) Barton CC, Ganey PE, Roth RA. Development of liver injury in rats treated with aflatoxin $B_1$ and endotoxin, and protection by neutrophil depletion. Toxicol Sci 48(1-S), 55, 1999.

116) Olivero J, Ganey PE. Interaction among signal transduction pathways in activation of rat neutrophils by polychlorinated biphenyls. Toxicol Sci 48(1-S), 278, 1999.

117) Ganey PE, Olivero J, Mahajerin A. Alterations in intracellular free calcium concentration induced by polychlorinated biphenyls in rat neutrophils. Toxicol Sci 48(1-S), 278, 1999.

118) Olivero J Ganey PE. Effects of polychlorinated biphenyls (PCBs) in fmlp-activated neutrophils are structure-dependent. Toxicol Sci 42(1-S), 29-30, 1998.

119) Yee SB, Ganey PE Roth RA. Temporal relationships in the augmentation of monocrotaline hepatotoxicity by bacterial endotoxin. Toxicol Sci 42(1-S), 366, 1998.

120) Kinser S, Yee S, Hill DA, Roth RA, Ganey PE. Bacterial endotoxin increases the hepatotoxic response to acute aflatoxin B1 exposure. Toxicol Sci 42(1-S), 365, 1998.

121) Roth RA, Kinser SA, Yee SB, Hill DA, Ganey PE. The augmentation of monocrotaline hepatotoxicity by bacterial endotoxin is not inhibited by gadolinium chloride. Toxicol Sci 42(1-S), 366, 1998.

122) Copple BL, Ganey PE, Moulin FM, Roth RA. The effect of thrombin in endotoxin-induced liver injury is not reproduced in neutrophil/hepatocyte cocultures. Toxicol Sci 42(1-S), 365, 1998.

123) Sneed RA, Jean PA, Ganey PE. Pentoxifylline, but not neutralization of TNF, attenuates LPS enhancement of allyl alcohol hepatotoxicity. The Toxicologist, Fund Appl Toxicol 36(No. 1, Pt. 2), 9, 1997.

124) Brown AP, Holdan WL, Ganey PE. Non-coplanar polychlorinated biphenyls stimulate neutrophil superoxide anion production. The Toxicologist, Fund Appl Toxicol 36(No. 1, Pt. 2), 291, 1997.

125) Ganey PE. Mechanisms of activation of neutrophils by polychlorinated biphenyls (PCBs). Fund Appl Toxicol, The Toxicologist, Fund Appl Toxicol 36(No.1, Pt. 2), 333, 1997.

126) Brown AP, Harkema JR, Roth RA, Ganey PE. Inhibition of Kupffer cell phagocytic function potentiates lipopolysaccharide-induced alveolitis. Fund Appl Toxicol, The Toxicologist 16, 45, 1996.

127) Tithof PK, Ruehle K, Ganey PE. Dieldrin and lindane activate neutrophils by a mechanism that involves calcium-independent phospholipase $A_2$. Fund Appl Toxicol, The Toxicologist 16, 54, 1996.

128) Ganey PE, Ho JS, Buchweitz JP, Roth RA. Identification of factors from rat neutrophils responsible for cytotoxicity to isolated hepatocytes. Fund Appl Toxicol, The Toxicologist 16, 81, 1996.

129) Tithof PK, Peters-Golden M, Ganey PE. A23187 and Aroclor 1242 activate distinct $PLA_2$s which are differentially linked to eicosanoid production and superoxide anion generation in neutrophils. Fund Appl Toxicol, The Toxicologist 16, 335, 1996.

130) Ganey PE. Signalling mechanisms in activation of neutrophils by xenobiotics. In Vitro 32, 16A, 1996.

131) Brown AP, Ng H, Jean PA, Ganey PE, Roth RA. Kupffer cell inactivation protects against lipopolysaccharide-induced hepatic injury despite neutrophil accumulation and tumor necrosis factor-α. The Toxicologist 15, 137, 1995.

132) Ganey PE. Mechanisms of neutrophil-mediated hepatocellular injury *in vitro*. The Toxicologist 15, 175, 1995.

133) Roth RA, Tithof PK, Ganey PE. Aroclor 1242 activates rat neutrophils by a mechanism independent of G proteins and protein tyrosine kinases. The Toxicologist 15, 188, 1995.

134) Tithof PK, Peters-Golden M, Ruhle K, Schiamburg L, Ganey PE. Aroclor 1242 activates neutrophils by a mechanism which involves phospholipase $A_2$. The Toxicologist 15, 188-189, 1995.

135) Bailie MB, Scozzaro MJ, Jean PA, Ganey PE, Roth RA. Gadolinium chloride attenuates acetaminophen hepatotoxicity in mice. The Toxicologist 15, 219, 1995.

136) Sneed RA, Grimes SD, Ganey PE. Lipopolysaccharide enhances the hepatotoxicity of allyl alcohol in Sprague-Dawley rats. The Toxicologist 15, 219-220, 1995.

137) Ganey PE, Brown AP, Schultze AE, Pearson JM. Potentiation of lipopolysaccharide-mediated hepatic injury by polychlorinated biphenyls (PCBs). The Toxicologist 15, 220, 1995.

138) Srinivasan R, Buchweitz JP, Ganey PE. Flutamide enhances neutrophil activation and causes neutrophil-mediated cytotoxicity to isolated hepatocytes. Amer J Gastroenterol 90, 1629, 1995.

139) Wagner JG, Ganey PE, Roth RA. Nitric oxide is not involved in hepatocyte killing by activated neutrophils *in vitro*. The Toxicologist 14, 246, 1994.

140) Tithof PK, Contreras ML, Ganey PE. Aroclor 1242 stimulates hydrolysis of

phosphoinositides in rat neutrophils. The Toxicologist 14, 249, 1994.

141) Brown AP, Ganey PE. Neutrophil degranulation and superoxide production induced by polychlorinated biphenyl is calcium-dependent. The Toxicologist 14, 948, 1994.

142) Ganey PE. Mechanism of activation of neutrophils and neutrophil-mediated toxicity. In Vitro 30A, 44, 1994.

143) Molnar RG, Wang P, Ayala A, Ganey P, Roth RA, Chaudry IH. Neutrophils play an integral role in depressing hepatocellular function in early sepsis. Shock 1(Suppl.), 22, 1994.

144) Sirois J, Schwartz DE, Roth RA, Ganey PE. Neutrophil (PMN) function after exposure to polychlorinated biphenyls (PCBs) *in vitro*. The Toxicologist 13, 1658, 1993.

145) Ganey PE, Bailie MB, Roth RA. Modulation of Kupffer cell function with gadolinium chloride does not alter methylene dialinine or allyl alcohol hepatotoxicity. The Toxicologist 13, 1693, 1993.

146) Narayanan PK, Lawler G, Ragheb K, Roth RA, Ganey P, Robinson JP. Inhibition of $H_2O_2$ production and CD11b expression of human neutrophils and HL-60 cells by the PCB Aroclor 1242. Cytometry Suppl. 6, 332D, 1993.

147) VanCise S, Bailie MB, Roth RA, Ganey PE. Activated neutrophils from rat injure isolated hepatocytes. The Toxicologist 12, 286, 1992.

148) Ganey PE, Lane W, Schwartz KA, Wilson M. Kupffer cell phagocytosis in isolated, perfused livers from iron-treated guinea pigs. The Toxicologist 12, 287, 1992.

149) Shobe EM, Ganey PE, Roth RA. The effects of some common volatile organic dumpsite chemicals (DSCs) on rat neutrophil (PMN) function *in vitro*. The Toxicologist 11, 198, 1991.

150) Lindert K, Kauffman F, Ganey P, Thurman R. Iron dextran selectively destroys non-parenchymal cells in the perfused rat liver. FASEB J, 5: A553, 1991.

151) Ganey PE, Lemasters JJ, Thurman RG. Fluorescent labeling to monitor Kupffer cell phagocytic activity in perfused rat liver. The Toxicologist 10, 61, 1990.

152) Ganey PE, Thurman RG. Ethanol (E) increases lethality of doxorubicin (DOX) to

cultured cells by elevating pyridine nucleotide redox state. FASEB J 3, A919, 1989.

153) Thurman RG, Ganey PE, Wu Y. Role of oxygen in regulation of substituted organic amines in perfused mouse liver. Proceedings, 4th International Symposium on Biological Oxidation of Nitrogen in Organic Molecules, Munich, Germany, 1989.

154) Ganey PE, Lemasters JJ, Thurman RG. A new method to monitor fluorescent labeling of endothelial cells during exposure to hepatotoxins in perfused rat livers. Abstract of the Fifth International Congress of Toxicology, Brighton, England, p. 31, 1989.

155) Thurman RG, Wu YR, Ganey PE, Kauffman FC, Belinsky S. Regulation of hepatic monooxygenation and glucuronidation by oxygen in the perfused rat liver. Abstracts of the Fifth International Congress of Toxicology, Brighton, England, p. 55, 1989.

156) Takei Y, Ganey P, Kauffman FC, Thurman RG. Ethanol potentiates hepatotoxicity due to menadione in perfused rat liver. Alcohol and Alcoholism 24, 259, 1989.

157) Ganey PE, Carter LS, Mueller RA, Thurman RG. Effect of oxygen tension on toxicity due to doxorubicin in perfused rat heart. The Pharmacologist 31, 165, 1989.

158) Ganey PE, Thurman RG. Hepatotoxicity due to menadione is potentiated by ethanol in perfused rat liver. The Toxicologist 8, 217, 1988.

159) Ganey PE, Sprugel KH, White SM, Wagner JG, Roth RA. Pulmonary hypertension caused by monocrotaline pyrrole (MCTP) is prevented by thrombocytopenia but not by antibodies to platelet-derived growth factor (PDGF). FASEB J 2, A1181, 1988.

160) Thurman RG, Ganey PE. Potentiation by ethanol of toxicity due to redox cycling compounds. Abstracts of Satellite Meeting on Liver Disease to IVth ISBRA Symposium, Tokyo, Japan, 1988.

161) Ganey PE, Roth RA. Serum copper and pulmonary hypertension in monocrotaline pyrrole-treated rats. Toxicologist 7, 198, 1987.

162) Ganey PE, Kauffman FC, Thurman RG. Regulation of oxygen-dependent hepatotoxicity due to adriamycin by reducing equivalent supply in perfused rat liver. Fed Proc 46, 2253, 1987.

163) Ganey PE, Roth RA. Thromboxane release by blood-perfused, isolated lungs from rats treated with monocrotaline pyrrole. Toxicologist 6, 63, 1986.

164) Ganey PE, Roth RA. Treatment with a thromboxane receptor antagonist does not alter monocrotaline pyrrole-induced pulmonary hypertension in rats. Fed Proc 45, 220, 1986.

165) Ganey PE, Sprugel KH, Boner KE, Roth RA. 5-Hydroxytryptamine receptor antagonists and monocrotaline pyrrole-induced cardiopulmonary toxicity. Toxicologist 5, 104, 1985.

166) Ganey PE, Roth RA. Thromboxane $B_2$ release in platelet-rich plasma from monocrotaline pyrrole-treated rats. Fed Proc 44, 918, 1985.

167) Ganey PE, Roth R.A. Treatment of rats with a thromboxane synthetase inhibitor (Dazmegrel) does not affect monocrotaline pyrrole-induced cardiopulmonary toxicity. Pharmacologist 27, 213, 1985.

168) Ganey PE, Roth RA. Release of 6-keto-prostaglandin $F_{1\alpha}$ and thromboxane $B_2$ from isolated perfused lungs of monocrotaline pyrrole-treated rats. Fed Proc 43, 808, 1984.

169) Ganey PE, Roth RA. Dietary restriction and cardiopulmonary toxicity of monocrotaline pyrrole. Fed Proc 42, 353, 1983.